预约演示
更新于：2026-07-15
Azithromycin
阿奇霉素
更新于：2026-07-15
概要
基本信息
简介阿奇霉素是一种小分子药物，作用于细菌核糖体的50S亚基，通过抑制蛋白质合成来杀死细菌。它是一种广谱抗生素，可用于治疗多种细菌感染，包括肺炎、中耳炎、喉炎、皮肤感染和生殖系统感染等。阿奇霉素在治疗呼吸道感染方面特别有效，可以缩短治疗时间和减少复发率。它也被用于治疗梅毒和麻疹等疾病。这种药物于1991年首次批准上市，原研公司为辉瑞公司，现已成为临床使用最广泛的抗生素之一。 |
药物类型 小分子化药 |
别名 Azithromycin (INN)、Azithromycin Dihydrate、Azithromycin Hydrate + [31] |
作用方式 抑制剂 |
作用机制 50S subunit抑制剂(50S核糖体亚基抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C38H72N2O12 |
InChIKeyMQTOSJVFKKJCRP-BICOPXKESA-N |
CAS号83905-01-5 |
关联
963
项与 阿奇霉素 相关的临床试验NCT07485010
A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to the standard treatments. It will also learn about the safety of this new combination antibiotic treatment when compared to the standard treatments. The main questions it aims to answer are:
* How well does Arm D treat mycobacterium abscessus pulmonary disease?
* What side effects does Arm D cause when used to treat mycobacterium abscessus pulmonary disease? Researchers will compare Arm D to the current standard of care treatments to see if Arm D treats mycobacterium abscessus pulmonary disease better and if it will cause less side effects.
Participants will:
* Be screened and recruited to the FORMaT adaptive platform trial (NCT04310930)
* Be given Arm D for 4 weeks or standard of care treatments for 6 weeks.
* Be reviewed by the study doctors weekly for checkups and tests.
* Provide respiratory samples (sample coughed up from the chest), respond to quality-of-life questionnaires, have CT lung scans and blood tests.
* How well does Arm D treat mycobacterium abscessus pulmonary disease?
* What side effects does Arm D cause when used to treat mycobacterium abscessus pulmonary disease? Researchers will compare Arm D to the current standard of care treatments to see if Arm D treats mycobacterium abscessus pulmonary disease better and if it will cause less side effects.
Participants will:
* Be screened and recruited to the FORMaT adaptive platform trial (NCT04310930)
* Be given Arm D for 4 weeks or standard of care treatments for 6 weeks.
* Be reviewed by the study doctors weekly for checkups and tests.
* Provide respiratory samples (sample coughed up from the chest), respond to quality-of-life questionnaires, have CT lung scans and blood tests.
开始日期2027-04-01 |
申办/合作机构 |
NCT07625228
Oral Azithromycin Versus Intramuscular Penicillin for Secondary Prevention of Rheumatic Heart Disease in Nigerian Secondary School Students: A Comparative Study to Improve Outcomes in Rheumatic Heart Disease Management
Background: Nigeria, among other Low and Middle-income countries, bears one of the highest burdens of RHD in Africa, affecting young to middle-aged adults within their productive years. This leads to loss of productivity, high out-of-pocket costs, and increased mortality risk. Challenges such as such as poverty, overcrowding, limited antibiotic access, and inconsistent prophylaxis contribute to the persistence of the disease. Secondary prophylaxis using intramuscular Benzathine Penicillin G (BPG) serves as the current standard for prevention, but has demonstrated poor adherence due to injection pain, fear, physical, and socioeconomic constraints. Oral Azithromycin offers a potential alternative by overcoming these barriers, providing an effective, acceptable, affordable and sustainable preventive strategy in Nigeria.
Methods and design: A randomised, non-inferiority, open-label, controlled clinical trial conducted across cardiology clinics of four tertiary hospitals in major Nigerian cities, for a duration of 24 months. This study will recruit participants aged 15 to 45 years with mild to moderate RHD cases (stage A or B as defined by World Heart Federation criteria) confirmed by a blinded adjudication panel, comprising 5 expert cardiologists, who will determine the echocardiographic stage of RHD on enrollment and at completion of the study period. Randomisation of participants will be done in a 1:1 ratio to receive either the standard regimen of intramuscular BPG (1.2 million units) every 28 days or a 3-day course of oral Azithromycin (500mg daily) repeated monthly. A total sample size of 474 participants will provide 90% power to demonstrate non-inferiority, using a margin of 4% with allowance for 15% on follow-up losses.
Objectives: The proportion of participants in the oral Azithromycin arm versus the IM BPG arm who demonstrate echocardiographic progression to worsen RHD stages or experience a recurrence of Acute Rheumatic Fever (ARF) within the period of two years will be compared. Additionally, accessing the adherence rates, causes of RHD-related hospitalisations, safety profiles, cost-effectiveness, and patient-reported outcomes, including treatment satisfaction and Health-Related Quality of Life (HRQoL).
Significance: This trial is designed to highlight the most effective and readily adoptable secondary prevention strategy for Nigeria's young-to-middle-aged population by evaluating patients' adherence, ease of administration, safety profile, drug availability, cost effectiveness, and other practical considerations in resource-limited settings. Establishing a prevention strategy that addresses the socioeconomic, physical barriers of injection-based prophylaxis and improving long-term adherence and clinical outcomes in Nigeria.
Methods and design: A randomised, non-inferiority, open-label, controlled clinical trial conducted across cardiology clinics of four tertiary hospitals in major Nigerian cities, for a duration of 24 months. This study will recruit participants aged 15 to 45 years with mild to moderate RHD cases (stage A or B as defined by World Heart Federation criteria) confirmed by a blinded adjudication panel, comprising 5 expert cardiologists, who will determine the echocardiographic stage of RHD on enrollment and at completion of the study period. Randomisation of participants will be done in a 1:1 ratio to receive either the standard regimen of intramuscular BPG (1.2 million units) every 28 days or a 3-day course of oral Azithromycin (500mg daily) repeated monthly. A total sample size of 474 participants will provide 90% power to demonstrate non-inferiority, using a margin of 4% with allowance for 15% on follow-up losses.
Objectives: The proportion of participants in the oral Azithromycin arm versus the IM BPG arm who demonstrate echocardiographic progression to worsen RHD stages or experience a recurrence of Acute Rheumatic Fever (ARF) within the period of two years will be compared. Additionally, accessing the adherence rates, causes of RHD-related hospitalisations, safety profiles, cost-effectiveness, and patient-reported outcomes, including treatment satisfaction and Health-Related Quality of Life (HRQoL).
Significance: This trial is designed to highlight the most effective and readily adoptable secondary prevention strategy for Nigeria's young-to-middle-aged population by evaluating patients' adherence, ease of administration, safety profile, drug availability, cost effectiveness, and other practical considerations in resource-limited settings. Establishing a prevention strategy that addresses the socioeconomic, physical barriers of injection-based prophylaxis and improving long-term adherence and clinical outcomes in Nigeria.
开始日期2027-01-05 |
NCT07443436
Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants
Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).
The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.
Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithromycin and hydroxychloroquine targeting endoplasmic reticulum stress, without demonstration of the efficacy of any of these treatments alone or in combination.
The investigators hypothesize that a treatment combining prednisone, azithromycin and hydroxychloroquine is safe and could improve the prognosis of adult patients with ILD associated with SRG variant.
Main objective and primary endpoint : Main objective:
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.
Primary endpoint:
Difference in forced vital capacity decline between the 2 groups at one year.
Secondary objectives and endpoints : Secondary objectives:
1. tolerance of the triple therapy,
2. correlation between the respiratory, radiological and clinical functional response,
3. quality of life of the patients,
4. overall survival, transplant-free survival, exacerbation free-survival, hospitalization-free survival
Secondary endpoints:
1. Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization)
2. Thoracic CT scan and PFT at 6 months and one year after randomization
3. Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,
4. Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization.
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care
Category : Category 2
Population of study participants: Patients aged over 18 years with ILD and SRG variant
Number of participants included : 30
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care.
The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.
Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithromycin and hydroxychloroquine targeting endoplasmic reticulum stress, without demonstration of the efficacy of any of these treatments alone or in combination.
The investigators hypothesize that a treatment combining prednisone, azithromycin and hydroxychloroquine is safe and could improve the prognosis of adult patients with ILD associated with SRG variant.
Main objective and primary endpoint : Main objective:
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.
Primary endpoint:
Difference in forced vital capacity decline between the 2 groups at one year.
Secondary objectives and endpoints : Secondary objectives:
1. tolerance of the triple therapy,
2. correlation between the respiratory, radiological and clinical functional response,
3. quality of life of the patients,
4. overall survival, transplant-free survival, exacerbation free-survival, hospitalization-free survival
Secondary endpoints:
1. Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization)
2. Thoracic CT scan and PFT at 6 months and one year after randomization
3. Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,
4. Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization.
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care
Category : Category 2
Population of study participants: Patients aged over 18 years with ILD and SRG variant
Number of participants included : 30
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care.
开始日期2026-10-01 |
100 项与 阿奇霉素 相关的临床结果
登录后查看更多信息
100 项与 阿奇霉素 相关的转化医学
登录后查看更多信息
100 项与 阿奇霉素 相关的专利（医药）
登录后查看更多信息
17,125
项与 阿奇霉素 相关的文献（医药）2026-12-31·European Clinical Respiratory Journal
Narrative review: mucus plugging in chronic obstructive lung diseases and bronchiectasis
Review
作者: Schou, Charlotte ; Genberg, Emma ; Kauppi, Paula ; Hisinger-Mölkänen, Hanna ; Mazur, Witold ; Kreivi, Hanna-Riikka ; Bjerrehave Nielsen, Line ; Thomander, Tuuli ; Mäkitalo, Laura
Background:
Mucus plugging, complete intraluminal occlusions, is recurrently found in high-resolution computer tomography images in obstructive lung diseases and is increasingly recognized as clinically meaningful.
Methods:
A narrative review on pathophysiology, clinical consequences and treatment of mucus plugging.
Results:
In bronchiectasis, mucus hypersecretion and plug formation are associated with infections, such as Pseudomonas aeruginosa and non-tuberculosis mycobacteria and correlated to exacerbations. In chronic obstructive pulmonary disease, mucus plugging is related to greater airflow obstruction, worse health status, higher exacerbation risk, and increased mortality. In asthma, mucus plugging is associated with severe asthma and poorer outcomes. Multiple scoring systems for mucus plugs in chest computed tomography (CT) have been introduced but definitions are heterogenous limiting comparability.
Conclusions:
Mucus plugs are measurable markers of disease activity with prognostic relevance across obstructive airway diseases. Clinical adoption is hindered by non‑standardized CT scoring and limited plug‑targeted trials. New treatment options for mucus plugging e.g. biologics in asthma have been found successful, especially dupilumab. Azithromycin as a part of prevention of infections in obstructive lung diseases is effective. Future research is needed to standardize and validate CT-based mucus-plug scoring systems that could be brought into clinical medicine.
2026-12-31·Journal of Oral Microbiology
Antimicrobial susceptibility testing of
Aggregatibacter Actinomycetemcomitans
can be performed using the EUCAST medium for anaerobic bacteria
Article
作者: Nørskov-Lauritsen, Niels ; Kahlmeter, Gunnar ; Jensen, Anne Birkeholm ; Matuschek, Erika
Background:
The oral bacterium Aggregatibacter actinomycetemcomitans (Aa) is associated with infectious diseases treated with antibiotics, but specific recommendations for antimicrobial susceptibility testing (AST) of the species do not yet exist. Objective To evaluate the possibility to perform AST of Aa following EUCAST guidelines using FAA-HB and 20 h incubation.
Method:
Twenty-nine Aa strains were analysed using disk diffusion on FAA-HB media from three manufacturers. Plates with with ampicillin and azithromycin disks were incubated in 5% CO2 and anaerobic conditions and examined after 20 and 44 h. Strains were additionally tested with the agar dilution method, and inhibition zone diameters (IZD) were correlated to the minimal inhibitory concentrations.
Results:
FAA-HB agar supported sufficient growth of Aa after 20 h incubation in 5% CO₂. No significant differences in IZD were found between the three media tested. Prolonged incubation (44 h) increased IZD, but 20 h incubation was adequate for reproducible results. Incubation in 5% CO₂ was superior to anaerobic conditions.
Conclusion:
Incubation in 5% CO2 and reading after 20 h incubation resulted in the best correlation between FAA-HB media from three manufacturers. The EUCAST disk diffusion method with FAA-HB for AST of Aa may be crucial for future standardization and development of clinical breakpoints for this species.
2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT
Comparative efficacy and safety of oral azithromycin versus doxycycline in moderate-to-severe Acne vulgaris: a systematic review and meta-analysis
Review
作者: Yaqoob, Raafay ; Ali Akbar, Makhzan ; Ali, Umair ; Mahin, Fakhar e ; Fazal, Menahil ; Maryam, Zoona ; Ahmed, Abu-Bakr ; Aminpoor, Hasibullah ; Silva Correia, Joao Victor ; Murtaza, Meer ; Batool, Asia ; Abbas, Muhammad Sharjeel ; Khattak, Muhammad Huzaifa
BACKGROUND:
Acne vulgaris is a chronic inflammatory disease and is one of the leading causes of dermatological morbidities among young adults. Doxycycline is widely recommended as first-line therapy for moderate to severe acne; however, its use is limited.
OBJECTIVE:
To systematically compare the efficacy and safety of oral azithromycin pulse therapy versus doxycycline in patients with moderate to severe acne vulgaris.
METHODS:
This systematic review and meta-analysis followed PRISMA guidelines. A comprehensive literature search on different databases was performed. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models based on heterogeneity.
RESULTS:
A total of 23 comparative studies comprising 2,769 patients were included. Pooled analysis demonstrated a statistically significant improvement in global acne severity favoring azithromycin (GAGS reduction: MD 1.81; 95% CI 1.28-2.34; I2 = 0%). Azithromycin achieved a significantly greater reduction in non-inflammatory lesion counts (MD -7.56; 95% CI -14.33 to -0.79). No significant differences were observed in inflammatory lesion reduction (MD 1.08; 95% CI -0.03 to 2.18).
CONCLUSION:
Oral azithromycin pulse therapy appears to have similar efficacy, better tolerability, and fewer side effects as compared to doxycycline.
1,004
项与 阿奇霉素 相关的新闻（医药）2026-07-15
·米内网
近日，时隔八年再度优化修订的2026新版《国家基本药物目录》正式落地实施。作为我国基层医疗卫生保障体系的核心用药指导清单，本轮目录调整紧扣“保基本、强基层、惠民生”核心导向，聚焦常见病、多发病诊疗需求，优化药品结构、严控用药成本、提升基层可及性，是深化医药卫生体制改革、夯实公共卫生服务体系的关键举措。米内网梳理政策信息了解到，海南葫芦娃药业集团凭借优质产品、突出临床价值与完善质量管控体系，共计12个品种新增纳入2026版《国家基本药物目录》，依托国家级政策红利，企业基层市场布局与高质量发展迎来全新机遇。
《国家基本药物目录》是规范临床用药、保障群众基本用药安全、节约医保基金支出的核心政策抓手，每一轮迭代更新均深刻重塑医药产业发展格局。时隔八年的基药目录扩容与优化，坚持安全有效、价格合理、保障可及、基层适宜四大原则，重点向基层刚需药、儿童专用药、经典中成药、慢病常用药倾斜，既有效填补基层用药品类短板、规范基层诊疗用药标准，也为具备研发实力、质量优势、民生属性的药企提供了广阔的下沉市场空间，实现民生普惠、产业提质、医保增效的三方共赢。
对比2018版《国家基本药物目录》，葫芦娃药业本次新增纳入的12个产品分为三类，明细如下：
①新增品种5个（富马酸丙酚替诺福韦片25mg、孟鲁司特钠咀嚼片4mg、孟鲁司特钠咀嚼片5mg、头孢克肟分散片0.1g、注射用艾司奥美拉唑钠40mg）；
②新增剂型5个（磷酸奥司他韦干混悬剂0.36g、吸入用乙酰半胱氨酸溶液3ml:0.3g、吸入用异丙托溴铵溶液2ml:0.5mg、盐酸溴己新注射液2ml:4mg、注射用阿奇霉素0.5g）；
③新增规格2个（氟康唑胶囊150mg、注射用头孢他啶2.0g）。
截至目前，葫芦娃药业此次12个品种新增后，2026新版《国家基药目录》中集团共有72个品种在册，涵盖儿科呼吸、消化慢病、抗感染、止咳化痰、心脑血管、妇科炎症、抗过敏、滋补类、颗粒剂、吸入雾化剂、注射剂、片剂、胶囊剂等多种剂型，涉及多个基层高频刚需治疗领域。
葫芦娃药业新增基药品种情况
本次新增的十二大品种均为临床认可度高、不良反应低、性价比突出的经典用药，长期广泛应用于全国各级医疗机构。本次集体纳入国家基药体系，是国家卫健、药监部门对葫芦娃药业产品的临床疗效、用药安全性、基层适配性、大众普惠性的权威认可。
随着基药政策全面落地，集团72个品种将全面覆盖乡镇卫生院、社区卫生服务中心等基层终端，大幅提升下沉渗透率。一方面，让基层百姓在家门口即可享受高品质、平价化的正规药品，切实解决基层用药品类少、优质药难获取的痛点，持续提升群众就医获得感；另一方面，基药准入红利将全面激活企业规模化产能，推动生产线满负荷高效运转，助力企业降本增效、稳固市场基本盘。同时，优质刚需基药的广泛替代应用，能够优化医保用药结构，有效节约国家医保经费，提升国家医保基金精细化、高效化利用水平。
近年来，葫芦娃药业始终坚持“创新+市场”双轮驱动发展战略，以科技创新为核心引擎持续赋能企业高质量发展。自2025年以来，企业科技创新成果密集落地、研发实力持续跃升，研发管线不断丰富、仿创转化效率显著提升、质量标准持续对标国标最高水平。在新药申报与获批层面，2025年企业接连斩获多项重磅药品注册证书，年内成功获批磷酸奥司他韦干混悬剂、二甲双胍恩格列净片(Ⅰ)、吸入用复方异丙托溴铵溶液、盐酸托莫西汀口服溶液、乳果糖口服溶液等多款化药新品，覆盖儿童抗病毒、成人慢病降糖、呼吸解痉、消化通便等多个刚需赛道，多款品种一次性通过仿制药质量和疗效一致性评价，药效质量与原研标准完全对标，具备全国基层大范围推广应用的资质与条件。
葫芦娃药业的磷酸奥司他韦干混悬剂获批情况
葫芦娃药业的二甲双胍恩格列净片(Ⅰ)获批情况
在产品迭代与专科布局层面，企业持续深耕儿童健康特色赛道，持续完善0-14岁全年龄段儿童用药体系，目前拥有40个儿童专属品种，儿科产品矩阵完备度、精细化程度位居行业前列。同时持续优化经典中成药工艺，对化积片、小儿康颗粒、蛇胆川贝液、生脉饮、小儿感冒颗粒等传统品种完成工艺升级与质量再提升，有效提高药品稳定性、适口性与临床依从性，更适配基层儿童、老年群体用药特点。
在科研体系与质量建设层面，2025年企业持续加大研发投入，完善仿制药改良、儿童专用制剂、中药经典名方优化三大研发方向，建立标准化、可溯源的生产质控体系，多款核心产品先后纳入国家级诊疗指南、临床路径推荐用药，产品循证医学价值持续夯实，品牌专业度与临床公信力稳步提升。
依托持续的技术创新、稳定的品质与品牌输出及清晰的产品战略布局，葫芦娃药业已形成儿科药特色突出、中西药协同、刚需品种密集、基层适配度高的核心产品壁垒，为集团72个品种集体入选国家基药目录奠定了坚实基础。
本次12个产品成功新增、72个品种纳入新版《国家基本药物目录》，是葫芦娃药业发展历程中的重要里程碑，标志着企业核心产品矩阵正式进入国家基本医疗保障主流体系，基层市场渠道、品牌影响力、产品覆盖面迎来全方位扩容。
葫芦娃药业已纳入基药目录品种
未来，葫芦娃药业将紧抓8年一遇的基药政策红利，持续坚守质量底线、深耕医药创新赛道，不断丰富优质、平价、安全的基层用药供给。同时依托基药准入优势，持续下沉基层医疗市场，完善终端布局、深化学术推广、赋能基层诊疗能力提升，全力推动国家基本药物制度落地惠民。企业将持续以科技创新驱动产业升级，以优质产品守护国民全生命周期健康，持续释放我国本土药企产能价值与社会价值，为我国基层医疗卫生事业高质量发展、医保基金高效统筹、全民用药普惠可及贡献坚实的企业力量。
免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092
【分享、点赞、在看】点一点不失联哦
2026-07-14
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
Clinical Infectious Diseases Volume 82 Issue Supplement_2
临床传染病学 82卷 增刊2期
https://academic.oup.com/cid/issue/82/Supplement_2
SUPPLEMENT（增刊）
Advancing Tuberculosis Research Through RePORT International: Enhancing Treatment Outcomes, Predicting Disease Progression, and Improving Diagnosis
通过结核病区域性前瞻性观察研究国际联盟（RePORT International）推动结核病研究：提高治疗效果、预测疾病进展及改善诊断
SUPPLEMENT ARTICLES（增补论著）
1
A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis
结核病区域性前瞻性观察研究国际联盟的叙述性综述：在抗击结核病中共享多样数据和样本
Rajita Bhavaraju and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S53–S59, https://doi.org/10.1093/cid/ciag151
2
Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review
长期肺部结核后遗症：一项叙述性综述
Akshay N Gupte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S60–S67, https://doi.org/10.1093/cid/ciag123
3
From Exposure to Disease: Predicting Tuberculosis Progression
从接触感染到发病：预测结核病进展
Mariana Araújo-Pereira and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S68–S74, https://doi.org/10.1093/cid/ciag125
4
Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications
疾病谱中的无症状结核：一项关于流行病学、诊断和公共卫生影响的范围综述
Beatriz Barreto Duarte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S75–S84, https://doi.org/10.1093/cid/ciag150
Clinical Infectious Diseases Volume 82 Issue 4
临床传染病学 82卷 4期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时光的传染病学技艺）
1
La Petite Vérole
天花
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page i, https://doi.org/10.1093/cid/ciag118
In the Literature（文献精选）
2
In the Literature
文献精选
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag013
Joint Editorial（联合社论）
3
Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases
随机对照试验方案：推动传染病领域透明度提升
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page 557, https://doi.org/10.1093/cid/ciag198
Clinical Dilemmas in Infectious Diseases（临床传染病疑难杂症）
4
Uncertain Terrain
不确定的领域
Kap Sum Foong and Sara W Dong
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 558–561, https://doi.org/10.1093/cid/ciaf283
Voices of ID（传染病之声）
5
Lessons I Learned from Our Soldier
我从我们的士兵身上学到的经验
Mitchell J Schwaber
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 562–563, https://doi.org/10.1093/cid/ciaf433
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
6
Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South
美国南部城市由瑞安·怀特资助的诊所中，HIV-1病毒血症患者使用长效卡博特韦/利匹韦林、来那卡帕韦和艾巴利珠单抗的情况
Jonathan A Colasanti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 564–574, https://doi.org/10.1093/cid/ciaf425
7
In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort
矛盾现象：在多中心艾滋病队列研究/妇女跨机构HIV研究联合队列中，尽管干燥血斑中磷酸替诺福韦水平低，但仍能实现病毒抑制
Sarah C Mann and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 575–582, https://doi.org/10.1093/cid/ciaf509
8
Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection
血液衰老表观遗传生物标志物在HIV-1感染控制良好人群中的预后价值
Patricia Martínez-Martín and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 583–591, https://doi.org/10.1093/cid/ciaf537
9
HIV Resistance to Dolutegravir Varies With Coadministered Agents
HIV对多替拉韦的耐药性随联合用药的不同而有所差异
Ingrid A Beck and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 592–596, https://doi.org/10.1093/cid/ciaf481
Immunocompromised Hosts（免疫功能低下宿主）
10
Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients
基于巨细胞病毒细胞介导免疫的莱特莫韦预防可改善异体基因造血干细胞移植受者的预后
Luxiang Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 597–606, https://doi.org/10.1093/cid/ciaf410
11
Changing Clinical and Laboratory Characteristics of Progressive Multifocal Leukoencephalopathy: A Retrospective National Cohort Study
进行性多灶性白质脑病临床和实验室特征的变化：一项回顾性全国队列研究
Ilaria Mainardi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 607–617, https://doi.org/10.1093/cid/ciaf501
12
Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort
嵌合抗原受体T细胞疗法后呼吸道合胞病毒感染：一项多中心回顾性队列研究中的风险因素和预后
Maria Isabel Sotelo-Alva and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 618–621, https://doi.org/10.1093/cid/ciag052
Respiratory Infections（呼吸道感染）
13
Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update
美国传染病学会（IDSA）立场声明：为何IDSA未认可《2025年社区获得性肺炎指南》更新版
Michael Klompas and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 622–624, https://doi.org/10.1093/cid/ciaf625
14
We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines
我们持不同意见：从《2025年社区获得性肺炎指南》中汲取的教训
Leila S Hojat and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 625–629, https://doi.org/10.1093/cid/ciaf626
15
Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays
社区获得性肺炎且呼吸道病毒检测呈阳性住院患者抗生素使用与预后的关联
Brett Biebelberg and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 630–638, https://doi.org/10.1093/cid/ciaf687
16
Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
联合β-内酰胺类药物治疗社区获得性肺炎的住院患者中，阿奇霉素与多西环素疗效的比较：一项多中心匹配队列研究
Yewande E Odeyemi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 639–647, https://doi.org/10.1093/cid/ciaf252
17
Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia
针对中度免疫功能低下肺炎住院患者，经验性抗生素对临床预后的目标试验模拟研究
Louis Saravolatz and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 648–657, https://doi.org/10.1093/cid/ciaf344
18
Impact of Respiratory Syncytial Virus Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis
呼吸道合胞病毒免疫接种对儿童急性中耳炎发生率的影响：一项时间序列分析
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 658–664, https://doi.org/10.1093/cid/ciaf564
Vaccines（疫苗）
19
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
使用LC16m8针对高危人群进行猴痘暴露前预防：一项开放标签随机试验
Nobumasa Okumura and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 665–672, https://doi.org/10.1093/cid/ciaf074
20
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
在感染人类免疫缺陷病毒的女性中，接种2剂与3剂九价人乳头瘤病毒疫苗的免疫原性和安全性：Papillon随机试验
Deborah Konopnicki and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 673–681, https://doi.org/10.1093/cid/ciaf241
21
Screening and Vaccination Rates for Tetanus, Hepatitis A, and Hepatitis B Among Individuals With Substance Use Disorders Hospitalized in an Integrated US Health System
在美国综合医疗机构中住院的成瘾性患者的破伤风、甲型肝炎和乙型肝炎筛查及接种率
Jennifer H Ku and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 682–688, https://doi.org/10.1093/cid/ciaf251
22
Atrial Fibrillation After Respiratory Syncytial Virus Vaccination Among Older Adults
老年人接种呼吸道合胞病毒疫苗后发生心房颤动的情况
Morgan Birabaharan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 689–691, https://doi.org/10.1093/cid/ciae649
23
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations
比较流感疫苗有效性的方法，以指导可能的优先产品推荐
Edward A Belongia and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 692–697, https://doi.org/10.1093/cid/ciaf563
Viral Infections（病毒性感染）
24
Clinical Features and Outcomes of Human Herpesvirus-6 DNAemia in Critically Ill Patients: A Retrospective Multicenter Analysis
危重患者人类疱疹病毒6型DNA血症的临床特征和预后：一项回顾性多中心分析
Margot Combet and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 698–708, https://doi.org/10.1093/cid/ciaf199
25
Kaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States
美国HIV感染肾捐赠者和移植受者中卡波西肉瘤相关疱疹病毒的风险和疾病
Puja H Nambiar and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 709–719, https://doi.org/10.1093/cid/ciaf229
26
Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat
接受特考韦瑞治疗的猴痘病患者的临床预后
Ciarra Leocadio and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 720–726, https://doi.org/10.1093/cid/ciaf520
27
Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs
大流行防范中的有效抗病毒药物：过去的错误，未来的需求
Antonios-Periklis Panagiotopoulos and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 727–733, https://doi.org/10.1093/cid/ciaf648
Photo Quizzes（影像问答）
28
From Soil to Skin: An Unexpected Cause of Necrotizing Cellulitis
从土壤到皮肤：坏死性蜂窝织炎的意外病因
Erica Peak and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 734–737, https://doi.org/10.1093/cid/ciaf555
29
A 67-year-Old Immunocompromised Male Presenting With Right Upper-Quadrant Abdominal Pain and Hepatic Lesions
一例67岁免疫功能低下男性，出现右上腹疼痛和肝脏病变
Sara Yousef Zadeh Shoushtari and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 738–741, https://doi.org/10.1093/cid/ciaf729
Bacterial Infections（细菌性感染）
30
Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study
金黄色葡萄球菌菌血症患者对静脉和口服抗生素治疗的自我报告认知、体验和偏好：一项描述性质性研究
Genevieve Walls and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e635–e642, https://doi.org/10.1093/cid/ciaf522
31
Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes
金黄色葡萄球菌菌血症临床亚型的可重复性识别
Maaike C Swets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e643–e651, https://doi.org/10.1093/cid/ciaf655
32
Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study
侵袭性肺炎球菌病的疾病趋势和死亡率：一项长期人群基础研究
Hörður Tryggvi Bragason and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e652–e661, https://doi.org/10.1093/cid/ciaf670
33
When and How to Use Subcutaneous Antibiotics
皮下注射抗生素的使用时机和方法
Stefano Di Bella and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e662–e673, https://doi.org/10.1093/cid/ciaf691
Clinical Trials（临床实验）
34
Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Clinical Trial to Influence Institutional Practice Transformation Towards Earlier Transition to Oral Antibiotics
利用口服与肠外抗菌治疗比较（COPAT）临床实验推动机构实践转型，以更早地过渡到口服抗生素治疗
Joy J Juskowich and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e674–e681, https://doi.org/10.1093/cid/ciaf707
35
The Fate of Oral Meds
口服药物的命运
Monica V Mahoney
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e682–e683, https://doi.org/10.1093/cid/ciaf708
36
Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies
接受吉泊西汀或呋喃妥因治疗的无并发症尿路感染患者的早期症状反应：两项关键性3期研究的汇总分析
Amanda J Sheets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e684–e692, https://doi.org/10.1093/cid/ciaf722
37
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial
HIV-1一线治疗失败人群中耐药突变发生率和决定因素的区域差异：D2EFT 3b/4期临床试验的子研究
Billal Musah Obeng and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e693–e704, https://doi.org/10.1093/cid/ciaf739
38
What's Hot This Year in ID Clinical Science 2025
2025年传染病临床学科领域的年度热点
Jeffrey A Freiberg and Patty W Wright
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e705–e709, https://doi.org/10.1093/cid/ciaf740
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
39
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV
阴道雌二醇对HIV感染女性绝经生殖泌尿综合征、阴道微生物群和黏膜免疫介质的影响
Kerry Murphy and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e710–e719, https://doi.org/10.1093/cid/ciaf669
40
Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin
在接受比克替拉韦/恩曲他滨/丙酚替诺福韦和利福平治疗的HIV相关结核病成人患者中，每日两次丙酚替诺福韦的药代动力学
Emmanuella Chinonso Osuala and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e720–e727, https://doi.org/10.1093/cid/ciaf732
41
Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care
整合HIV和兴奋剂使用障碍治疗：在HIV护理中开展应急管理试点实施效果试验
Ayesha Appa and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e728–e734, https://doi.org/10.1093/cid/ciag006
42
Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity
美国HIV和乙型肝炎核心抗体阳性人群在转换为无抗乙肝病毒活性的抗逆转录病毒治疗后乙型肝炎复发的队列研究
Rachel V Denyer and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e735–e742, https://doi.org/10.1093/cid/ciag001
43
Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B Virus-Active Antiretroviral Therapy
接受无抗乙肝病毒活性的抗逆转录病毒治疗的HIV感染者乙型肝炎病毒复发情况
Amir M Mohareb and Anders Boyd
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e743–e745, https://doi.org/10.1093/cid/ciag002
44
The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
终止美国疾病控制与预防中心对HIV检测资助的潜在影响：对18个州的建模研究
Ruchita Balasubramanian and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e746–e754, https://doi.org/10.1093/cid/ciag038
45
Cutting Federal Funds for HIV Testing Means Not Ending the HIV Epidemic
削减HIV检测的联邦资金意味着无法终结HIV流行
Sarah E Scott and Joshua A Barocas
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e755–e756, https://doi.org/10.1093/cid/ciag039
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
46
Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital
西拉查医院普通内科病房强化碳青霉烯类耐药肠杆菌科细菌预防计划的整群随机对照试验
Apiradee Taweesuk and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e757–e764, https://doi.org/10.1093/cid/ciaf523
47
Risk Factors Associated With Progression to Clinical Candida auris Infection Among Adults With Previous Colonization—Florida, 2019–2023
2019-2023年佛罗里达州既往定植的成人进展为临床耳念珠菌感染的相关风险因素
Katharine E Saunders and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e765–e772, https://doi.org/10.1093/cid/ciaf551
48
Using Generative Artificial Intelligence to Identify Central Line–associated Bloodstream Infections
利用生成式人工智能识别中心静脉导管相关血流感染
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e773–e780, https://doi.org/10.1093/cid/ciaf636
49
Infection Control in Carceral Facilities
监狱设施中的感染控制
Amadin A Olotu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e781–e790, https://doi.org/10.1093/cid/ciaf479
50
Infection Prevention and Control in Carceral Settings
监狱环境中的感染预防与控制
April N McDougal and Lara B Strick
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e791–e793, https://doi.org/10.1093/cid/ciaf480
51
Impact of Discontinuation of Contact Precautions on Healthcare-associated Extended Spectrum β-Lactamase-Producing Escherichia coli in a Large Tertiary Care Hospital: An Interrupted Time-series Analysis
一家大型三级医院停止接触预防措施对医院获得性产超广谱β-内酰胺酶大肠埃希菌的影响：一项中断时间序列分析
Stefano Musumeci and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e794–e798, https://doi.org/10.1093/cid/ciaf594
Respiratory Infections（呼吸道感染）
52
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis
美国医疗保险参保老年人因需就医的呼吸道合胞病毒疾病后患吉兰-巴雷综合征的风险评估：一项自我对照病例系列分析
Caihua Liang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e799–e806, https://doi.org/10.1093/cid/ciaf621
53
Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2
独立检测以加速甲型流感、乙型流感和严重急性呼吸系统综合征冠状病毒2型侧流层析检测法的开发
Anuradha Rao and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e807–e815, https://doi.org/10.1093/cid/ciaf660
54
Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries
在四个高负担国家，与痰液分子检测相比，舌拭子检测对结核病的诊断效果
Caitlin A Moe and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e816–e823, https://doi.org/10.1093/cid/ciag077
55
Are We Ready for the Gift Tongues Can Give to Tuberculosis?
我们准备好接受舌头为结核病诊断带来的“馈赠”了吗？
Michael R Barer
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e824–e825, https://doi.org/10.1093/cid/ciag078
Sexually Transmitted Infections（性传播感染）
56
Evaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests: An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada
评估实施和扩大梅毒快速/即时检测使用的影响：加拿大阿尔伯塔省新发梅毒阳性率的中断时间序列分析
L Alexa Thompson and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e826–e835, https://doi.org/10.1093/cid/ciaf651
57
Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals
男男性行为者中与人乳头瘤病毒相关的肛门癌前病变：暴露前预防用药者与HIV阳性者的对比研究
Magali Surmont and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e836–e842, https://doi.org/10.1093/cid/ciaf724
58
Is 3 Really What We Need? Relative Effectiveness of Benzathine Penicillin G and Doxycycline Treatment Regimens for Late or Unknown Duration Syphilis in 6 US Jurisdictions, 2016–2021
我们需要“3”吗？2016-2021年美国6个司法管辖区晚期或病程不明梅毒患者使用苄星青霉素G和多西环素治疗方案的相对疗效
River A Pugsley and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e843–e851, https://doi.org/10.1093/cid/ciag099
59
Strong Real-World Evidence That a Single Dose of Benzathine Penicillin G or a 28-Day Course of Oral Doxycycline Is Not Inferior to 3 Doses of Benzathine Penicillin G for the Treatment of Late Latent or Unknown Duration Syphilis
强力现实证据表明，单剂苄星青霉素G或28天口服多西环素治疗晚期潜伏梅毒或病程不明梅毒的疗效并不逊于3剂苄星青霉素G
Noah Kojima and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e852–e854, https://doi.org/10.1093/cid/ciag101
Vaccines（疫苗）
60
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
对≥50岁成年人，在初次接种12个月后再次接种针对呼吸道合胞病毒的mRNA疫苗mRNA-1345的安全性、耐受性和免疫原性
Jaya Goswami and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e855–e862, https://doi.org/10.1093/cid/ciaf515
61
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine
在NVX-CoV2373重组蛋白疫苗PREVENT-19有效性试验中，抗体标志物作为严重新型冠状病毒肺炎风险免疫相关因素的分析
Youyi Fong and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e863–e874, https://doi.org/10.1093/cid/ciaf558
62
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
现在是时候重新评估全球人乳头瘤病毒疫苗接种的目标年龄了吗？
Edie Brassington and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e875–e883, https://doi.org/10.1093/cid/ciaf679
63
Preschool or Infant Human Papillomavirus Immunization?
学龄前还是婴儿期接种人乳头瘤病毒疫苗？
Mark A Kane and Eduardo L Franco
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e884–e886, https://doi.org/10.1093/cid/ciaf678
Correspondence（读者来信）
64
Caution in Interpreting Equivalence From Nonsignificant Findings in Antiretroviral Switch Studies
谨慎解读抗逆转录病毒药物转换研究中非显著性结果得出的等效性结论
Esteban Martinez
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e887–e888, https://doi.org/10.1093/cid/ciaf675
65
Clarifying INSTINCT: Switching From Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Shows Comparable Inflammatory and Weight Outcomes
阐明INSTINCT研究：从多替拉韦/拉米夫定转换为比克替拉韦/恩曲他滨/丙酚替诺福韦显示出相似的炎症和体重结果
Sergio Serrano-Villar and Santiago Moreno
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e888–e889, https://doi.org/10.1093/cid/ciaf676
66
Can Doxycycline Prophylaxis Indirectly Reduce Congenital Syphilis?
多西环素预防能否间接降低先天性梅毒的发生率？
Kalpana Gopalkrishnan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e889–e891, https://doi.org/10.1093/cid/ciaf694
67
The Urgency of Now: Congenital Syphilis in the Doxycycline Post-exposure Prophylaxis Era
迫在眉睫：多西环素暴露后预防时代的先天性梅毒问题
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page e891, https://doi.org/10.1093/cid/ciaf695
68
Routine HIV RNA Testing During Injectable Cabotegravir and Oral Preexposure Prophylaxis Use
注射用卡博特韦和口服暴露前预防用药期间进行常规HIV RNA检测
Angelo Roberto Raccagni and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e891–e892, https://doi.org/10.1093/cid/ciaf702
69
Simplifying Testing for Human Immunodeficiency Virus During Pre-exposure Prophylaxis Monitoring
简化暴露前预防监测期间的人类免疫缺陷病毒检测
Weiming Zhu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e892–e893, https://doi.org/10.1093/cid/ciaf703
70
Methodological Considerations in Evaluating Oral Antivirals for B-Cell-Depleted Patients
评估B细胞耗竭患者口服抗病毒药物的方法学考量
Wenjing Chen and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e893–e894, https://doi.org/10.1093/cid/ciaf717
71
Target Trial Emulation of Oral Antivirals for B-Cell-Depleted COVID-19 Patients—Reply to Chen et al
B细胞耗竭型新型冠状病毒肺炎患者口服抗病毒药物的靶试验模拟——回复Chen等人的评论
Xiaofeng F Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e894–e895, https://doi.org/10.1093/cid/ciaf718
72
Misleading Conclusion That Is Not in Accordance With the Results of the Reported Randomized, Controlled Trial
与所报告的随机对照试验结果不符的误导性结论
Charlotte Strøm
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e895–e896, https://doi.org/10.1093/cid/ciaf659
73
Vaccine Policy Pendulum: A Lesson From Japan
疫苗政策摇摆不定：日本的教训
Masaki Machida and Wakaba Fukushima
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e896–e897, https://doi.org/10.1093/cid/ciaf689
74
Herpes Zoster, Vaccine, and Stroke Risk
带状疱疹、疫苗与中风风险
Shih-Wei Lai and Sheng-Chun Chiu
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e897–e898, https://doi.org/10.1093/cid/ciaf725
Clinical Infectious Diseases Volume 82 Issue Supplement_4
临床传染病学 82卷 增刊4期
https://academic.oup.com/cid/issue/82/Supplement_4
SUPPLEMENT（增刊）
IDWeek Industry Highlights 2025
传染病之周2025 行业亮点
SUPPLEMENT ARTICLES（增补论著）
1
Selected Industry Highlights From IDWeek 2025
传染病之周2025 精选行业亮点
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S85–S86, https://doi.org/10.1093/cid/ciag206
2
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
HIV感染者内脏腹部脂肪过多的不同表现：两例临床病例展示特沙莫瑞林与胰高血糖素样肽-1受体激动剂的不同治疗路径
Robin Beach and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S87–S91, https://doi.org/10.1093/cid/ciag121
3
Metagenomic Next-generation Sequencing in Central Nervous System Infections: Clinical Strategies, Evidence, and Best Practices
宏基因组二代测序在中枢神经系统感染中的应用：临床策略、证据与最佳实践
Greer Waldrop and Sumanth P Reddy
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S92–S99, https://doi.org/10.1093/cid/ciag120
Clinical Infectious Diseases Volume 82 Issue 5
临床传染病学 82卷 5期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Vaccination Detail, Detroit Industry
疫苗接种细节，底特律工业
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page i, https://doi.org/10.1093/cid/ciag119
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag180
Voices of ID（传染病之声）
3
Infected With the Academic Bug
染上学术热
Sigrun Einarsdottir
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 743–744, https://doi.org/10.1093/cid/ciaf546
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
4
Predictive Value of C-reactive Protein for Hospitalization and Mortality Among People With Advanced HIV Disease in Uganda Receiving the World Health Organization-recommended Package of Care
C反应蛋白对乌干达接受世界卫生组织推荐治疗方案的晚期HIV疾病患者住院和死亡的预测价值
Elizabeth L Schwartz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 745–752, https://doi.org/10.1093/cid/ciaf560
5
Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial
塞马谷肽对HIV感染者认知功能的影响：一项随机对照试验
Ornina Atieh and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 753–761, https://doi.org/10.1093/cid/ciaf577
6
Earlier Initiation of Treatment Following HIV Acquisition Reduces Non-AIDS-defining Malignancy Risk
HIV感染后尽早启动治疗可降低非艾滋病相关性恶性肿瘤风险
Iris A J van der Wulp and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 762–772, https://doi.org/10.1093/cid/ciaf595
7
Let's Get It Started: Early Antiretroviral Treatment After HIV Acquisition Reduces Non–AIDS-Defining Malignancies
让我们开始吧：HIV感染后尽早启动抗逆转录病毒治疗可减少非艾滋病相关性恶性肿瘤
Nancy Crum
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 773–775, https://doi.org/10.1093/cid/ciaf596
8
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006–2023
2006–2023年西班牙HIV感染者年龄相关健康结局的趋势
Javier Martínez-Sanz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 776–784, https://doi.org/10.1093/cid/ciaf622
9
Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens
当代抗逆转录病毒方案随机试验中新发HIV-1耐药性
Josep M Llibre and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 785–798, https://doi.org/10.1093/cid/ciaf471
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
10
Mycobacterium tuberculosis Transmission in Healthcare Settings: A Systematic Review of Frequency, Risk Factors, and Exposure Conditions
医疗机构中结核分枝杆菌传播：频率、危险因素及暴露条件的系统综述
Fizza Manzoor and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 799–807, https://doi.org/10.1093/cid/ciag053
Medical Microbiology（医学微生物学）
11
Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital
脑脊液宏基因组二代测序：一家三级转诊医院首年经验
Sergio Alvarez Mulett and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 808–814, https://doi.org/10.1093/cid/ciaf390
12
Navigating Nomenclature in Patient Care: Taxonomy Considerations From the College of American Pathologists’Microbiology Committee
患者诊疗中的命名导航：美国病理学家学会微生物学委员会的分类学考量
Jennifer Dien Bard and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 815–821, https://doi.org/10.1093/cid/ciaf474
13
Implementing Point-of-Care Testing in Infectious Diseases
在感染性疾病中实施床旁检测
Jean-Claude Nguyen Van and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 822–828, https://doi.org/10.1093/cid/ciaf650
Mycobacterial Infections（分枝杆菌感染）
14
Impact of Diabetes Mellitus in Tuberculosis (TB) Patients on TB Transmission
糖尿病对结核病（TB）患者TB传播的影响
Chuan-Chin Huang and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 829–840, https://doi.org/10.1093/cid/ciaf647
15
Association of Mycobacterium avium paratuberculosis With Crohn's Disease: A Large Multicenter Study From a Tuberculosis-Endemic Region
副结核分枝杆菌与克罗恩病的关联：来自结核病流行地区的一项大型多中心研究
Sudheer Kumar Vuyyuru and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 841–847, https://doi.org/10.1093/cid/ciaf738
16
Short-Course Tuberculosis Preventive Therapy in a High Migration Setting: Early Experience With 1HP in Cook County, Illinois
高移民背景下的短程结核病预防性治疗：库克县（伊利诺伊州）1HP方案的早期经验
Samuel Starke and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 848–851, https://doi.org/10.1093/cid/ciaf723
17
Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study
低剂量英夫利昔单抗在中枢神经系统结核炎性并发症中的作用：一项回顾性队列研究
Selwyn Selva Kumar D and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 852–856, https://doi.org/10.1093/cid/ciaf573
18
Targeting Inflammation in Tuberculous Meningitis Treatment
靶向结核性脑膜炎治疗中的炎症
Guy E Thwaites
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 857–859, https://doi.org/10.1093/cid/ciaf574
Pediatric and Maternal Infectious（儿科与孕产妇感染）
19
A 15-year Single-center Analysis of Late-onset Group B Streptococcus Infection Correlating Clinical Severity With Pathogen Virulence Determinants
晚发型B族链球菌感染的15年单中心分析：临床严重程度与病原体毒力因子的相关性
Carl Britto and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 860–867, https://doi.org/10.1093/cid/ciaf603
20
Evaluating Personal and Environmental Decolonization Strategies for Children With Skin and Soft Tissue Infection and Their Households — A Randomized Clinical Trial
评估皮肤和软组织感染儿童及其家庭的个人与环境去定植策略——一项随机临床试验
Alaina L Robinson and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 868–877, https://doi.org/10.1093/cid/ciaf627
Surgical Infectious Diseases（外科感染）
21
Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE
万古霉素耐药肠球菌（VRE）主动围手术期预防对VRE定植肝移植受者的影响
Giulia Jole Burastero and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 878–887, https://doi.org/10.1093/cid/ciaf121
22
Cephalosporins Versus Non-cephalosporin Antibiotics for Perioperative Prophylaxis in Primary Arthroplasty: A Systematic Review and Meta-Analysis
头孢菌素与非头孢菌素类抗生素在初次关节置换术围手术期预防中的比较：系统综述与荟萃分析
Rita Igwilo-Alaneme and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 888–900, https://doi.org/10.1093/cid/ciag172
Photo Quizzes（影像问答）
23
Safari Souvenir: A Case of Fever in a Returning Traveler
safari纪念品：一例返程旅行者发热病例
Nicole L Kusnik and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 901–903, https://doi.org/10.1093/cid/ciag129
24
Diagnostic Pitfalls—When First Appearances Can Deceive
诊断陷阱——当表象具有欺骗性
Annie Caldwell and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 904–907, https://doi.org/10.1093/cid/ciag044
Clinical Trials（临床试验）
25
Evaluation of a Remote Therapeutic Monitoring Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy
远程治疗监测设备与综合护理平台在门诊肠外抗微生物治疗中的评估
Emily A Siegrist and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e899–e909, https://doi.org/10.1093/cid/ciag009
26
Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial
多替拉韦降低人T淋巴细胞病毒1型前病毒载量并改善神经系统预后：一项2期对照试验
Carlos Brites and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e910–e920, https://doi.org/10.1093/cid/ciag163
27
Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy
多替拉韦似乎可降低人T淋巴细胞病毒1型（HTLV-1）前病毒载量：HTLV-1相关脊髓病治疗的新兴理性方法
Eric A Meyerowitz
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e921–e922, https://doi.org/10.1093/cid/ciag164
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers
长效新冠与急性新冠疫苗接种后综合征的临床表现重叠：表型、严重程度及生物标志物
Lawrence Purpura and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e923–e931, https://doi.org/10.1093/cid/ciaf624
29
Integrating Genomic Data into Test-negative Designs for Estimating Lineage-specific COVID-19 Vaccine Effectiveness
将基因组数据整合入检测阴性设计以估计谱系特异性COVID-19疫苗有效性
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e932–e941, https://doi.org/10.1093/cid/ciag059
Hepatitis（肝炎）
30
Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV
HIV感染者经直接抗病毒药物治疗丙型肝炎病毒后肝细胞癌的风险
Daniela K van Santen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e942–e950, https://doi.org/10.1093/cid/ciaf635
31
Fatal Overdose, Acute Viral Hepatitis, and HIV Attributed to Injection Drug Use, Appalachian Region of the United States, 2000–2023
阿巴拉契亚地区2000–2023年注射吸毒导致的致命过量、急性病毒性肝炎及HIV
Danae Bixler and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e951–e959, https://doi.org/10.1093/cid/ciaf730
32
Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024
利用大型商业实验室剩余血清估算丙型肝炎患病率及病毒清除率：2023年11月至2024年9月
Megan G Hofmeister and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e960–e966, https://doi.org/10.1093/cid/ciag007
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
33
State AIDS Drug Assistance Programs’Contribution to the US Viral Suppression, 2015–2022
美国各州艾滋病药物援助项目对全美病毒抑制的贡献，2015–2022年
Kathleen A McManus and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e967–e973, https://doi.org/10.1093/cid/ciag034
34
Centering AIDS Drug Assistance Programs in the US HIV Response
将艾滋病药物援助项目置于美国HIV应对的核心
Benjamin P Linas
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e974–e975, https://doi.org/10.1093/cid/ciag035
35
Association of Immunodeficiency and HIV Viremia With Cervical Precancer and Cancer Risk Among Women With HIV in South Africa
南非HIV感染女性中免疫缺陷和HIV病毒血症与宫颈癌前病变及癌症风险的关联
Yann Ruffieux and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e976–e983, https://doi.org/10.1093/cid/ciag093
36
Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies
MK-8527（一种口服核苷逆转录酶转位抑制剂）在既往未接受过抗逆转录病毒治疗的HIV-1感染成人中的抗逆转录病毒活性、药代动力学及安全性：来自两项开放标签1期研究的结果
Russ P Carstens and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e984–e991, https://doi.org/10.1093/cid/ciag135
37
Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term Pre-exposure Prophylaxis Adherence for US Men Who Have Sex With Men in Pilot RCT
床旁尿液替诺福韦药物浓度反馈咨询改善美国男男性行为者长期暴露前预防用药依从性——一项先导随机对照试验
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e992–e995, https://doi.org/10.1093/cid/ciag080
Mycobacterial Infections（分枝杆菌感染）
38
Diagnostic Accuracy of the STANDARD F TB-Feron FIA Assay for Tuberculosis Infection in Vietnam: A Cross-Sectional Study
STANDARD F TB-Feron FIA检测在越南结核感染诊断中的准确性：一项横断面研究
Han Thi Nguyen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e996–e1004, https://doi.org/10.1093/cid/ciaf561
39
Asymptomatic Tuberculosis in Children With Household Exposure to Mycobacterium tuberculosis
有结核分枝杆菌家庭接触史儿童中的无症状结核病
Humphrey Mulenga and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1005–e1013, https://doi.org/10.1093/cid/ciaf562
40
Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment
利福平暴露及临床基线协变量对肺结核治疗反应影响的深入认识
Marie Wijk and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1014–e1022, https://doi.org/10.1093/cid/ciaf586
41
Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures
靶向免疫治疗的结核感染筛查建议：美国处方信息、临床资源与质量指标的比较
Matthew T Murrill and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1023–e1035, https://doi.org/10.1093/cid/ciaf628
42
Pharmacokinetics of Dexamethasone in Tuberculous Meningitis
地塞米松在结核性脑膜炎中的药代动力学
Jose M Calderin and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1036–e1042, https://doi.org/10.1093/cid/ciaf642
43
One Piece in the Puzzle of Tuberculous Meningitis: Dexamethasone Pharmacokinetics
结核性脑膜炎拼图中的一块：地塞米松药代动力学
Tjip S van der Werf and Marieke G G Sturkenboom
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1043–e1044, https://doi.org/10.1093/cid/ciaf644
44
Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine—An Approach for Clinical Management
临床表型用于结核精准医学的未来前景——一种临床管理方法
Katarina Niward and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1045–e1052, https://doi.org/10.1093/cid/ciaf663
Pediatric and Maternal Infectious Diseases（儿科与孕产妇感染）
45
Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa
南非夸祖鲁-纳塔尔省接受新型及重新利用药物治疗耐多药/利福平耐药结核病的女性的母婴预后
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1053–e1062, https://doi.org/10.1093/cid/ciaf593
46
Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa
南非耐多药/利福平耐药结核病孕妇与全口服6个月方案：一例系列患者的经验
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1063–e1071, https://doi.org/10.1093/cid/ciag032
47
Human Cytomegalovirus (HCMV) Shedding and T-cell Immune Responses in HCMV-seropositive Women During Pregnancy and Postpartum: Prevalence, Natural History, and Risk Factors
HCMV血清阳性女性孕期及产后人巨细胞病毒（HCMV）排毒和T细胞免疫应答：患病率、自然史及危险因素
Shari Sapuan and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1072–e1082, https://doi.org/10.1093/cid/ciag076
Vaccines（疫苗）
48
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old
奥密克戎BA.1适配BNT162b2 COVID-19疫苗第四剂在18–55岁成人中的安全性和免疫原性
Patricia Winokur and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1083–e1092, https://doi.org/10.1093/cid/ciag026
49
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years
AS01E佐剂呼吸道合胞病毒（RSV）预融合F蛋白疫苗在18–49岁RSV高风险成人中与≥60岁成人的免疫原性和安全性比较
Essack Mitha and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1093–e1103, https://doi.org/10.1093/cid/ciag058
50
Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalization and Emergency Department Visits Associated With Respiratory Syncytial Virus in Older Adults: A Meta-analysis
RSVpreF和RSVpreF3疫苗在预防老年人RSV相关住院和急诊就诊中的真实世界有效性：一项荟萃分析
Dewan Md Sumsuzzman and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1104–e1111, https://doi.org/10.1093/cid/ciag107
51
Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345
实体器官移植受者的呼吸道合胞病毒疫苗接种：mRNA-1345三期试验中期结果
Erick F Mayer and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1112–e1121, https://doi.org/10.1093/cid/ciag108
Photo Quiz（影像问答）
52
Crusted, Chronic, and Confusing
结痂、慢性化与困惑
Luisa Hurtado-Rossi and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1122–e1125, https://doi.org/10.1093/cid/ciaf583
Correspondence（读者来信）
53
Unmasking the Hidden Guests: Referral and Secondary Infection Biases in Cutibacterium Endocarditis
揭开隐藏的访客：Cutibacterium心内膜炎中的转诊偏倚和二次感染偏倚
Shuo Li and Lin Wang
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1126, https://doi.org/10.1093/cid/ciaf733
54
Reply to Willoughby on the Demise of the Milwaukee Protocol for Rabies
对Willoughby关于密尔沃基狂犬病方案终结的回复
Alan C Jackson and Thiravat Hemachudha
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1126–e1127, https://doi.org/10.1093/cid/ciaf734
55
Estimating Vaccine Effectiveness Against Symptomatic Infection From Its Effectiveness Against Asymptomatic Infection
从无症状感染的疫苗有效性估算有症状感染的疫苗有效性
Eyal Shahar
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1127–e1128, https://doi.org/10.1093/cid/ciaf735
56
Contextualizing On-Therapy Resistance Development With Novel Antibiotics: Interplay Between Timing of Therapy Initiation and Critical Illness–Linked Pharmacokinetic/Pharmacodynamic Unpredictability
新型抗生素治疗中耐药产生的情境化解读：治疗启动时机与危重疾病相关药代动力学/药效学不可预测性之间的相互作用
Dilip Dubey and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1128–e1129, https://doi.org/10.1093/cid/ciag010
57
The Clinical Thermometer as the First Home Test for Infectious Disease
临床体温计：感染性疾病的首个家用检测工具
Michele Augusto Riva
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1129–e1130, https://doi.org/10.1093/cid/ciag030
58
Methodology Misrepresented: Correcting the Record on the American Thoracic Society Community-acquired Pneumonia Guideline Process
方法论被歪曲：更正美国胸科学会社区获得性肺炎指南制定过程的记录
Kevin C Wilson and Eyal Oren
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1130–e1131, https://doi.org/10.1093/cid/ciag040
59
Misleading Comments About the Impact of Early Bacillus Calmette-Guerin Vaccination on Neonatal and Infant Mortality
关于早期卡介苗接种对新生儿和婴儿死亡率影响的误导性评论
Peter Aaby and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1131–e1132, https://doi.org/10.1093/cid/ciag065
60
Questioning Non-inferiority: Methodological Concerns in the Meta-analysis of Oral vs Intravenous Therapy for Staphylococcus aureus Bacteremia
质疑非劣效性：金黄色葡萄球菌菌血症口服与静脉治疗荟萃分析中的方法学问题
Dawd S Siraj and Fauzia Hollnagel
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1132–e1133, https://doi.org/10.1093/cid/ciag070
61
Problems With Electronic Health Record Penicillin Allergy Mislabeling and Recommendations for Their Correction
电子健康记录中青霉素过敏标注错误的问题及纠正建议
David J Witt and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1134, https://doi.org/10.1093/cid/ciag086
62
Complex Problem, Digital Cure? Rethinking Penicillin Allergy Relabeling Using Technology-Enabled Care
复杂问题，数字解药？利用技术赋能护理重新思考青霉素过敏重新标注
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1135–e1137, https://doi.org/10.1093/cid/ciag084
Clinical Infectious Diseases Volume 82 Issue Supplement_5
临床传染病学 82卷 增刊5期
https://academic.oup.com/cid/issue/
SUPPLEMENT（增刊）
ADVANCE-ID: Conducting Innovative Clinical Trials and Promoting Access for Antibiotics in Asia
ADVANCE-ID：在亚洲开展创新临床试验并推动抗生素可及性
SUPPLEMENT ARTICLES（增补论著）
1
Advancing Clinical Evidence in Infectious Diseases: An Infectious Diseases Clinical Trials Network for Asia, the “Antimicrobial Resistance Hot Zone”
推进感染病临床证据：面向亚洲——这一"耐药热点区域"——的感染性疾病临床试验网络
David L Paterson
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S101–S104, https://doi.org/10.1093/cid/ciag122
2
Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World
多重耐药革兰阴性杆菌管理的全球调查：高收入国家与世界其他地区的实践差异
Abi Manesh and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S105–S115, https://doi.org/10.1093/cid/ciag025
3
Efficacy and Safety of Newer Antibiotics Versus Generic Antibiotics for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
新型抗生素与仿制抗生素治疗医院获得性及呼吸机相关性细菌性肺炎的疗效与安全性：随机对照试验的系统综述与荟萃分析
Anh T K Nguyen and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S116–S125, https://doi.org/10.1093/cid/ciag045
4
Antibiotic Clinical Trials: A Review of the Past, Present Challenges, and Potential Solutions
抗生素临床试验：回顾过去、当前挑战及潜在解决方案
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S126–S137, https://doi.org/10.1093/cid/ciag017
5
Considerations in Designing Clinical Trials of Novel Antibacterial Agents Using a Superiority Design
采用优效性设计开展新型抗菌药物临床试验的考量
David L Paterson and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S138–S146, https://doi.org/10.1093/cid/ciag207
6
Consent Modes and Consent Rates in Randomized Controlled Trials for Severe Infections: A Scoping Review
严重感染随机对照试验中的知情同意方式与同意率：范围性综述
Yiyun Shou and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S147–S153, https://doi.org/10.1093/cid/ciaf715
7
Challenges to Accessing Newer Antibiotics for Multidrug-resistant Bacterial Infections in Asia: A Literature Review of Multi-Stakeholder Perspectives
亚洲多重耐药细菌感染中获取新型抗生素的挑战：多利益相关方视角的文献综述
Alec F Aligui and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S154–S161, https://doi.org/10.1093/cid/ciag024
Clinical Infectious Diseases Volume 82 Issue 6
临床传染病学 82卷 6期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（传染病艺术长河）
1
Cover Illustration for Camus' The Plague, 1948
加缪《鼠疫》封面插画，1948年
Michael B Grizzard and Mary Grizzard
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page i, https://doi.org/10.1093/cid/ciag182
In the Literature（文献札记）
2
In the Literature
文献札记
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag181
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Contemporary Ambulatory Approach to Adult Fever of Unknown Origin
前沿综述：成人不明原因发热的当代门诊诊疗方案
William F Wright and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 909–926, https://doi.org/10.1093/cid/ciag158
Ethics Rounds（伦理巡诊）
4
Antibiotics in Hospice: Applying the Four-Quadrant Approach to Improve Patient-Centered Care
安宁疗护中的抗菌药物使用：运用四象限诊疗模式优化以患者为中心的照护
Patrick D Crowley and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 927–930, https://doi.org/10.1093/cid/ciag057
Voices of ID（传染病之声）
5
I Died—and Was Brought Back to Life—Twice
我两次濒死，又重获新生
Richard E. Sutton
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 931–933, https://doi.org/10.1093/cid/ciaf612
Antimicrobial Resistance and Stewardship（抗生素耐药与管理）
6
Using Encounter-Level Data for Risk-Adjustment of Antimicrobial Use Comparisons: Feasibility and Variable Selection
利用就诊层面数据开展抗菌药物使用对比的风险校正：可行性与变量筛选研究
Rebekah W Moehring and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 934–943, https://doi.org/10.1093/cid/ciaf682
7
Moving Closer to Patient-Level Risk Adjustment for Hospital Antimicrobial Use
推进住院患者抗菌药物使用的个体化风险校正体系构建
Jonathan D Baghdadi and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 944–945, https://doi.org/10.1093/cid/ciaf683
8
Macrolide and Nonmacrolide Resistance After 36 Months of Mass Azithromycin Distribution in Burkina Faso: A Cluster Randomized Trial
布基纳法索大规模阿奇霉素分发36个月后大环内酯类与非大环内酯类耐药情况：一项整群随机对照试验
Catherine E Oldenburg and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 946–953, https://doi.org/10.1093/cid/ciag051
9
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients: A Pragmatic, Randomized Trial
基于社区获得性肺炎发病概率为住院患者个体化选用抗菌药物：一项实用性随机对照试验
Jonathan D Baghdadi and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 954–961, https://doi.org/10.1093/cid/ciag126
10
ALARA in Antimicrobial Stewardship: Adapting Radiation Safety Principles to Address Antibiotic Overuse
抗菌药物管理中的ALARA原则：借鉴辐射安全理念管控抗生素过度使用
Zachary T Aldewereld and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 962–967, https://doi.org/10.1093/cid/ciaf688
Clinical Practice and Policy（临床实践与医疗政策）
11
Assessment of an Infectious Disease eConsult Service at a Large Mid-Atlantic Healthcare System
美国中大西洋大型医疗体系感染病线上会诊服务应用效果评估
Ava Hunt and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 968–970, https://doi.org/10.1093/cid/ciaf736
12
H.U.S.T.L.E: A Consult Fitness Guide for Infectious Diseases Providers
H.U.S.T.L.E指南：感染科医师会诊工作实操指南
Gonzalo Bearman and Priya Nori
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 971–975, https://doi.org/10.1093/cid/ciaf672
13
More Than a Message: Death by a 1000 “Chats”
不止简单文字沟通：无休止线上问诊带来的诊疗困境
Darcy Wooten and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 976–978, https://doi.org/10.1093/cid/ciag094
14
The Erosion of a Pillar of Public Health: ACIP's Role and the Future of US Vaccine Policy Post-June 2025
公共卫生支柱职能削弱：美国免疫实践咨询委员会的职能变迁与2025年6月后疫苗政策走向
Edwin J Asturias and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 979–985, https://doi.org/10.1093/cid/ciag042
15
Worldwide Impact of ACIP's 2025 Overhaul
2025年美国免疫实践咨询委员会政策修订的全球影响
Louis Bont and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 986–987, https://doi.org/10.1093/cid/ciag043
Hepatitis（肝炎）
16
Trends in Reflexive Hepatitis C Virus Testing in a National US Laboratory: A Retrospective Study From 2018 to 2024
美国国家级实验室丙型肝炎病毒 reflex联动检测趋势：2018–2024年回顾性研究
Min Kyung Lee and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 988–992, https://doi.org/10.1093/cid/ciag227
17
Sofosbuvir/Velpatasvir Concentrations in the Breastmilk of Postpartum Women With Opioid Use Disorder Receiving Treatment for Hepatitis C Virus: A Pharmacokinetic Study
合并阿片类物质使用障碍的产后丙肝治疗女性母乳中索磷布韦/维帕他韦药物浓度：药代动力学研究
Catherine A Chappell and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 993–996, https://doi.org/10.1093/cid/ciaf443
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
18
Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study
当前抗逆转录病毒治疗时代，基于CD4计数与年龄划分的HIV感染者社区获得性肺炎、带状疱疹发病风险：一项纵向队列研究
Elsemieke te Linde and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 997–1006, https://doi.org/10.1093/cid/ciaf686
19
Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance
病毒学抑制HIV感染者转换为比克替拉韦/丙酚替诺福韦/恩曲他滨方案或多替拉韦+富马酸替诺福韦二吡呋酯/恩曲他滨方案：有无替诺福韦耐药人群真实世界转归
Alain Makinson and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1007–1014, https://doi.org/10.1093/cid/ciaf726
20
Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles
HIV感染者转换长效卡博特韦/利匹韦林后的乙肝转归：病毒再激活、新发感染及不同血清学状态下肝脏安全性
Alberto Foncillas and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1015–1022, https://doi.org/10.1093/cid/ciag023
21
Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications
长效注射卡博特韦联合利匹韦林治疗发生病毒学失败：亚型、血药浓度、耐药突变及临床诊疗意义分析
Maria Mazzitelli and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1023–1031, https://doi.org/10.1093/cid/ciag046
22
What Are the Causes and Consequences of Virological Failure on Long-acting Cabotegravir/Rilpivirine?
长效卡博特韦/利匹韦林方案病毒学失败的诱因与临床后果
Andrew Hill and Chloe Orkin
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1032–1034, https://doi.org/10.1093/cid/ciag047
Parasitic Infections（寄生虫感染）
23
Cerebral Malaria and Severe Malarial Anemia, but not Other Forms of Severe Malaria, Are Associated With Long-Term Cognitive Impairment
脑型疟疾与重症疟疾性贫血（其余重症疟疾亚型除外）与远期认知损伤相关
Paul Bangirana and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1035–1041, https://doi.org/10.1093/cid/ciaf712
24
Not All Forms of Severe Malaria Impair Long-term Cognition—More Characterization, More Questions
并非所有重症疟疾均会造成长期认知损害——仍需更多分层研究与探索
Karl B Seydel and Stephen T J Ray
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1042–1043, https://doi.org/10.1093/cid/ciaf713
25
Frequent Plasmodium ovale Recurrence in Coastal Tanzania
坦桑尼亚沿海地区卵形疟原虫高复发率研究
Kelly Carey-Ewend and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1044–1051, https://doi.org/10.1093/cid/ciag199
26
Invisible Malarias
隐匿性疟疾
J Kevin Baird
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1052–1053, https://doi.org/10.1093/cid/ciag201
Sexually Transmitted Infections（性传播疾病）
27
A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study
男男性行为人群及跨性别女性每日口服HIV联合性病暴露前预防（富马酸替诺福韦二吡呋酯/恩曲他滨加多西环素）先导随机对照试验：DuDHS研究
Troy Grennan and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1054–1062, https://doi.org/10.1093/cid/ciaf043
28
A New Choice for Doxycycline Prophylaxis
多西环素暴露前预防新选择
Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1063–1064, https://doi.org/10.1093/cid/ciaf044
29
Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial
服用多西环素暴露后预防男性的耐药淋病奈瑟菌感染情况：ANRS 174 DOXYVAC子研究
Béatrice Berçot and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1065–1074, https://doi.org/10.1093/cid/ciaf591
30
Sustained Effectiveness of Doxycycline Post-Exposure-Prophylaxis in a Large Sexual Health Clinic Over 96 Weeks: An Interrupted Time Series Analysis
大型性病诊疗中心多西环素暴露后预防96周持续有效率：间断时间序列分析
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1075–1078, https://doi.org/10.1093/cid/ciaf234
Photo Quiz（影像问答）
31
A 3-Year-Old Girl With a Chest Wall Mass
3岁女童胸壁肿块一例
Deema Gashgarey and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1079–1081, https://doi.org/10.1093/cid/ciag028
32
Why Are Gonorrhea Case Rates Declining in the United States? A Research Agenda
美国淋病报告病例数下降原因：后续研究方向展望
Kirstin I Oliveira Roster and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1082–1090, https://doi.org/10.1093/cid/ciaf690
33
Fever in a Man with Uncontrolled HIV
HIV控制不佳男性发热病例
Tristan Jones and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1091–1095, https://doi.org/10.1093/cid/ciag056
Antimicrobial Resistance and Stewardship（抗生素耐药与管理）
34
Human Cases of Carbapenemase-Producing Escherichia coli Linked to Spread Between Animals and the Environment in a Veterinary Facility—Massachusetts, USA, 2023
2023年美国马萨诸塞州：动物诊疗机构内动物与环境传播引发人感染产碳青霉烯酶大肠埃希菌病例
Ian M DeStefano and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1138–e1144, https://doi.org/10.1093/cid/ciaf541
35
Carbapenemase-Producing Enterobacterales in Pets: A New Threat From Veterinary Clinics
宠物携带产碳青霉烯酶肠杆菌目细菌：动物诊所带来的新型感染威胁
Vincent Perreten and Andrea Endimiani
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1145–e1147, https://doi.org/10.1093/cid/ciaf544
36
Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study
青霉素过敏口服药物激发试验：国际抗生素过敏协作网络（iNAAN）研究
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1148–e1162, https://doi.org/10.1093/cid/ciag082
37
Direct Oral Challenge for Penicillin Allergy: A Hospital Implementation Evaluation Via the International Network of Antibiotic Allergy Nations (iNAAN) Study
青霉素过敏口服激发试验院内落地实施效果评估——基于国际抗生素过敏协作网络（iNAAN）研究
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1163–e1170, https://doi.org/10.1093/cid/ciag083
Bacterial Infections（细菌感染）
38
Clinical Manifestations, Long-Term Trends, and Risk Factors for Treatment Failure in Native Vertebral Osteomyelitis: A 26-Year Mayo Clinic Experience
原发性椎体骨髓炎临床表现、26年长期发病趋势及治疗失败危险因素：梅奥诊所单中心经验
Takahiro Matsuo and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1171–e1180, https://doi.org/10.1093/cid/ciag048
39
The Management of Native Vertebral Osteomyelitis Remains Unchanged: Are Additional Trials Necessary?
原发性椎体骨髓炎诊疗方案无实质性更新：是否仍需开展更多临床试验？
Werner Zimmerli
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1181–e1183, https://doi.org/10.1093/cid/ciag049
40
Clinical Characteristics and Survival of Hospitalized Anthrax Patients with Pleural, Pericardial, or Peritoneal Fluid Collections
合并胸腔、心包、腹腔积液的住院炭疽患者临床特征与生存预后
Jon-Erik C Holty and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1184–e1193, https://doi.org/10.1093/cid/ciag113
41
Uncomplicated Urinary Tract Infections: From an Invisible Impact to a Visible Change in Complex Care
单纯性尿路感染：从隐匿疾病负担到复杂诊疗体系的诊疗变革
Rafael Cantón and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1194–e1199, https://doi.org/10.1093/cid/ciaf705
Emerging Infections（新型感染）
42
Six Cases of Borealpox and Evidence of a Zoonotic Source: Alaska, 2020–2023
2020–2023年阿拉斯加6例北极痘病例及动物源性传播证据
Eric Q Mooring and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1200–e1207, https://doi.org/10.1093/cid/ciaf497
43
Measles Without Rash During Acute Febrile Illness Surveillance in Tanzania, 2023–2024
2023–2024年坦桑尼亚急性发热监测中无皮疹麻疹病例
Saning'o Lukumay and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1208–e1215, https://doi.org/10.1093/cid/ciaf582
44
Melioidosis Complicated by Native Valve Endocarditis in a Traveler Returning From Thailand to the United States
泰国归国旅行者罹患类鼻疽合并原生瓣膜心内膜炎
Akash Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1216–e1221, https://doi.org/10.1093/cid/ciag003
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
45
Hepatocellular Carcinoma Survival in People With and Without HIV in the United States, 2001–2019
2001–2019年美国HIV阳性与阴性人群肝细胞癌生存预后对比
Jennifer K McGee-Avila and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1222–e1231, https://doi.org/10.1093/cid/ciag137
46
Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa
多替拉韦方案对比依非韦伦方案抗逆转录病毒治疗重大心血管不良事件风险：基于南非匿名常规医疗数据的模拟目标试验
Jienchi Dorward and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1232–e1241, https://doi.org/10.1093/cid/ciag155
47
Patterns of HIV-1 Viral Load Suppression and Drug Resistance During the Dolutegravir Transition: A Population-based Longitudinal Study
全面切换多替拉韦治疗期间HIV-1病毒载量抑制水平与耐药突变特征：一项人群纵向研究
Michael A Martin and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1242–e1251, https://doi.org/10.1093/cid/ciag161
48
Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024
合并2型糖尿病的HIV感染者与非感染者肾脏及心血管并发症：瑞典HIV发病队列研究（COSMOHS）2010–2024数据
Isabela Killander Möller and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1252–e1261, https://doi.org/10.1093/cid/ciag261
49
Progression Risk in Cancer Patients with HIV Compared with Cancer Patients Without HIV
HIV阳性肿瘤患者相较于阴性患者的疾病进展风险
Derek Schneider and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1262–e1265, https://doi.org/10.1093/cid/ciag170
Infections in Older Adults（老年人群感染）
50
Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries
急性呼吸道感染老年患者呼吸道合胞病毒疾病负担：欧洲六国前瞻性研究
Manel Terns Riera and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1266–e1276, https://doi.org/10.1093/cid/ciag146
51
Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons
连续三个流行季欧洲老年呼吸道合胞病毒感染者健康相关生活质量调查
Manel Terns Riera and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1277–e1288, https://doi.org/10.1093/cid/ciag147
52
The Renaissance of Respiratory Syncytial Virus Diagnosis: How Understanding Burden Can Inform Clinical Practice and Demonstrate the Benefit of Vaccines
呼吸道合胞病毒诊断技术革新：明晰疾病负担指导临床实践、印证疫苗获益价值
Angela R Branche
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1289–e1291, https://doi.org/10.1093/cid/ciag148
Mycobacterial Infections（分枝杆菌感染）
53
Hidden in Success: Gendered Patterns of Suboptimal Care Engagement Among Tuberculosis Patients Who“Successfully” Completed Treatment in South Africa
治愈背后的隐忧：南非“治疗成功”结核患者就医依从性的性别差异
Andrew Medina-Marino and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1292–e1301, https://doi.org/10.1093/cid/ciaf714
54
Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings
两大高结核负担临床中心痰Xpert Ultra微量阳性成人及青少年结核患病率与预测因素
Caitlin Visek and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1302–e1310, https://doi.org/10.1093/cid/ciag019
55
“Trace-MTB” on Sputum Xpert Ultra: New Evidence for Interpretation in High-burden Settings
痰Xpert Ultra“微量结核分枝杆菌”阳性：高结核负担地区判读新证据
Bianca Sossen and Neil Martinson
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1311–e1312, https://doi.org/10.1093/cid/ciag018
56
Diagnostic Accuracy of Molecular Testing on Saliva and Oral Swabs for Pulmonary Tuberculosis
唾液与口腔拭子分子检测对肺结核的诊断效能
Deninson Alejandro Vargas and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1313–e1321, https://doi.org/10.1093/cid/ciag055
57
Documenting Environmentally Acquired Mycobacterium intracellulare subsp. chimaera Pulmonary Disease Soon After Bronchiectasis Onset
支气管扩张发病后短期内确诊环境源性奇美拉胞内分枝杆菌肺病病例报道
Jennifer R Honda and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1322–e1325, https://doi.org/10.1093/cid/ciag015
58
We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness
我国对贝达喹啉耐药危机应对准备不足：呼吁完善临床与公共卫生防控体系
Gail Brenda Cross and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1326–e1332, https://doi.org/10.1093/cid/ciag008
Respiratory Infections（呼吸道感染）
59
Long-term Clinical Outcomes After Hospitalization for Acute Respiratory Illness Due to Respiratory Syncytial Virus
呼吸道合胞病毒急性呼吸道感染住院患者远期临床结局
David Singer and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1333–e1344, https://doi.org/10.1093/cid/ciaf710
60
Microbial Detection in Community-Acquired Pleural Space Infections Using the BIOFIRE Joint Infection Panel and Individual Polymerase Chain Reaction Assays
采用BIOFIRE关节感染试剂盒与单重PCR检测社区获得性胸腔感染病原体
Portia Mira and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1345–e1352, https://doi.org/10.1093/cid/ciag050
61
Diagnostic Performance of New Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis Infection: An Updated Systematic Review and Meta-analysis
新型商业化γ干扰素释放试验诊断结核分枝杆菌感染的效能：更新系统综述与荟萃分析
Lika Apriani and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1353–e1364, https://doi.org/10.1093/cid/ciag102
Viral Infections（病毒感染）
62
Symptomatic and Asymptomatic Norovirus Infections in Early Life; the PREVAIL Cohort, 2017–2020
婴幼儿诺如病毒显性与隐性感染：PREVAIL队列2017–2020年数据
Julia M Baker and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1365–e1374, https://doi.org/10.1093/cid/ciag033
63
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions—A Retrospective Cohort Study in the United States
≥18岁合并基础疾病成人带状疱疹分年龄发病风险：美国回顾性队列研究
Rachel A Cohen and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1375–e1383, https://doi.org/10.1093/cid/ciag095
64
Herpes Simplex Virus Type 1 Encephalitis: A Prospective Population-Based Cohort Study
1型单纯疱疹病毒性脑炎：一项基于人群的前瞻性队列研究
Lærke Storgaard Duerlund and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1384–e1392, https://doi.org/10.1093/cid/ciag136
Photo Quiz（影像问答）
65
Multifocal Cutaneous Abscesses
多发皮肤脓肿病例
Shrruthi Velavan and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1393–e1396, https://doi.org/10.1093/cid/ciag074
Correspondence（读者来信）
66
New French Guidelines on Subcutaneous Antibiotic Therapy: A Response to Di Bella et al.
法国皮下注射抗生素新版指南发布——回应Di Bella等人研究
Emmanuel Forestier and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1397–e1398, https://doi.org/10.1093/cid/ciag088
67
Time to Appropriate Therapy and Antimicrobial Resistance-Attributable Mortality
抗菌药物及时给药时长与耐药相关死亡风险
Tatsuhiko Nanri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1398, https://doi.org/10.1093/cid/ciag087
68
Is Time to Appropriate Therapy a Mediator of Mortality Associated With Antimicrobial Resistance?
抗菌药物及时给药时长是否介导耐药相关死亡风险？
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1398–e1399, https://doi.org/10.1093/cid/ciag090
69
Request for Additional Details on the COPAT Trial
恳请补充COPAT试验详细研究数据
Brad Spellberg and Bassam Ghanem
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1399, https://doi.org/10.1093/cid/ciag100
70
Additional Details on the COPAT Trial
COPAT试验补充研究细节回复
Joy J Juskowich and Arif R Sarwari
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1399–e1401, https://doi.org/10.1093/cid/ciag103
71
Zinc: An Oft-forgotten Component in the Management of Diarrhea
锌剂：腹泻治疗中常被忽视的关键药物
Indi Trehan
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1401, https://doi.org/10.1093/cid/ciag111
72
I Zinc, Therefore I Am: Context is Key
锌剂不可或缺：临床应用需结合具体场景
Andi L Shane and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1401–e1402, https://doi.org/10.1093/cid/ciag112
73
When IS900 Positivity is not the Tie-Breaker: Interpreting Mycobacterium avium Subspecies paratuberculosis Signals Across Crohn's Disease and Intestinal Tuberculosis in a Tuberculosis-Endemic Setting
IS900阳性结果不可作为鉴别金标准：结核高发区克罗恩病与肠结核中副结核分枝杆菌判读要点
Yuanli Yang
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1402–e1403, https://doi.org/10.1093/cid/ciag127
74
MAP Detection: Identifying a Pathogenic Driver Rather Than a Diagnostic Marker
副结核分枝杆菌检测：识别致病驱动因素而非单纯诊断标志物
Sudheer Kumar Vuyyuru and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1403–e1405, https://doi.org/10.1093/cid/ciag128
75
Composite End Points, Minor Anomalies, and Missed Work-Ups: Making 12-Month Infant “Unfavorable Outcomes” Interpretable After BDLLfx/BDLCfz in Pregnancy
复合终点、轻微异常与漏诊评估：解读孕期BDLLfx/BDLCfz方案暴露婴儿12个月不良结局
Yuanli Yang
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1405–e1406, https://doi.org/10.1093/cid/ciag142
76
Responding Appropriately to Safety Signals in Infants Exposed to the 6-month BDLLfx/BDLCfz Regimen In Utero
妥善处置宫内暴露6个月BDLLfx/BDLCfz方案婴儿的安全预警信号
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1406–e1407, https://doi.org/10.1093/cid/ciag143
2026-07-14
·生物通
高风险抗生素在当代传染病实践中仍然不可或缺，但它们占了可预防毒性、治疗药物监测复杂性和抗菌药物管理工作量中不成比例的份额。万古霉素、氨基糖苷类、多粘菌素、利奈唑胺、达托霉素、部分β-内酰胺类以及两性霉素B尤其具有挑战性，因为临床相关的暴露-毒性关系与显著的个体间差异和分散的上市后安全性监测并存。人工智能和真实世界证据越来越多地被提议作为应对这些局限性的补充方法，尽管证据基础仍然参差不齐且主要为回顾性。本叙述性综述综合了PubMed/MEDLINE、Scopus和Web of Science中2019年至2026年4月间发表的文献，并通过引文追踪和监管药物警戒资源进行补充，研究优先考虑实施成熟度、外部验证状态和管理相关性。当前证据表明，当嵌入临床丰富的数据环境时，人工智能可能改善安全性监测：机器学习模型在万古霉素、多粘菌素和利奈唑胺治疗中的肾毒性和血液学毒性方面显示出有前景的区分能力；自然语言处理可能增强从临床文本中提取不良药物事件；贝叶斯方法和模型知情工具已在万古霉素和氨基糖苷类给药中显示出临床实用性。然而，前瞻性实施数据仍然稀少，外部验证不常见，并且证明这些工具改善真实世界抗生素安全性结局（而非单纯的预测区分能力）的证据仍然有限。因此，人工智能驱动的抗生素安全性监测正从方法论前景向条件性临床实用性过渡，而非已证明的获益。近期价值最可能来自与治疗药物监测、抗菌药物管理和药理学主导的临床审查的整合，而非自主决策，临床药理学家和管理团队应主导这些工具的本地实施、验证和治理。**1. 引言** 高风险抗生素是指治疗暴露与临床重要毒性之间的安全范围较窄，或其毒性频繁到需要结构化监测、剂量调整和管理监督的药物。在常规医院实践中，这类药物包括万古霉素、氨基糖苷类、多粘菌素、利奈唑胺、达托霉素以及部分β-内酰胺类（如头孢吡肟），后者在肾功能不全患者中易出现浓度相关的神经毒性。两性霉素B（amphotericin B）是此抗菌范围中的唯一例外：它属于抗真菌而非抗菌药物，但被有意纳入而非偶然，因为它与本文讨论的抗生素面临相同的根本毒性监测问题——强效疗效受限于剂量限制性器官毒性和对实验室监测的依赖。因此，其纳入基于毒理学和监测方面的理由，而非抗菌药物类别，全文将其作为比较对象而非额外抗菌药物进行讨论。这些药物对于多重耐药感染、深部革兰阳性菌病、严重脓毒症和复杂门诊肠外抗菌治疗（OPAT）至关重要，但同时也是最易引发肾毒性、神经毒性、血细胞减少、肝毒性或治疗中断的抗感染药物之一。 抗生素相关不良药物反应（ADRs）在住院患者中常见。观察性研究表明，抗生素是住院期间不良事件中涉及的主要药物类别之一，荟萃分析证据表明，疑似ADRs与老年住院患者住院时间延长、费用增加和临床结局恶化相关。更常见的事件（包括万古霉素治疗期间血清肌酐升高、利奈唑胺相关血小板减少症或头孢吡肟相关脑病）可能迫使降阶梯治疗、延迟感染源控制、延长住院时间并使管理决策复杂化。 传统的药物警戒虽必要，但不足以应对这一挑战。自发报告系统能捕获罕见和意外的安全性信号，但受限于漏报、重复提交、缺乏暴露分母、因果关系评估可变以及浓度依赖性毒性的延迟识别。这些局限性在抗生素中尤为重要，因为许多毒性效应发生在急性疾病、多药联用、肾功能不全和快速变化的生理状态背景下，使得因果关系归因在床边和上市后监测中都变得困难。值得注意的是，人工智能并不能解决这些根本局限性；它可能在一定条件下缓解其中一些问题。 人工智能（AI）和真实世界证据（RWE）正作为应对传统药物警戒某些不足的实用方法而出现。AI可扩展在结构化和非结构化数据中检测模式的能力，而RWE通过利用电子健康记录（EHRs）、索赔数据、登记系统、自发报告系统和数字监测工具，拓宽了临床试验之外的证据基础。然而，对这些方法的热情必须与以下认识相平衡：该领域目前正经历人工智能炒作周期，这并不总能转化为经过临床验证的工具。核心问题已不再是AI能否促进抗生素安全性监测，而是特定应用能否以及如何被严格验证、负责任地治理并有意义地嵌入临床工作流程。 本综述旨在总结AI驱动的高风险抗生素安全性监测的现有证据，解决一个具体问题：在何种条件下，人工智能和真实世界证据可望改善常规临床实践中抗生素相关毒性的检测、预测和预防。研究人员预期并对照现有文献进行了检验：AI驱动的工具在治疗药物监测（TDM）和剂量个体化这一狭窄领域显示出最可靠的临床效用证据，而在声称自主安全监测的更广泛领域证据最不成熟。综述强调RWE来源、TDM、实施障碍以及与传染病服务、临床药理学家和抗菌药物管理（AMS）团队相关的临床未来方向，并有意将证据质量的批判性评估置于单个研究的描述性摘要之上，将AI主要定位为支持管理工作流程的工具，而非自主的药物警戒系统。本综述区别于近期一篇更广泛讨论AI在细菌感染管理中应用的叙述性综述：本文并非调查诊断、抗菌药物选择和整体感染管理，而是专注于特定高风险药物组的安全性监测、药物警戒、TDM和毒性预测，并在整个过程中对预测性能与已证明的临床获益之间的区别应用一致的批判性视角。**2. 方法** 本文设计为叙述性综述而非系统综述。其目的是提供一种解释性、以临床为重点的综述，涵盖传染病、临床药理学、药物警戒、生物医学信息学和监管科学等不断发展的文献。未预先注册正式方案，也未准备PRISMA流程图，这与叙述性设计一致。然而，鉴于方法学透明度的重要性，研究人员详细描述了检索和选择过程，以便进行批判性评估。 **2.1 文献检索** 对截至2026年4月30日收录于PubMed/MEDLINE、Scopus和Web of Science的出版物进行了结构化检索。核心PubMed检索字符串将AI方法术语（人工智能、机器学习、深度学习、自然语言处理、贝叶斯、大型语言模型）与抗生素相关术语（万古霉素、氨基糖苷类、多粘菌素、利奈唑胺、达托霉素、β-内酰胺类、头孢吡肟、两性霉素B）以及药物警戒相关术语（安全性、毒性、不良药物反应、药物警戒、治疗药物监测、电子健康记录、FAERS、EudraVigilance）相结合。检索策略针对Scopus和Web of Science进行了调整，使用了等效的主题词。两性霉素B作为唯一的抗真菌比较对象被纳入检索字符串，因为它与范围内的抗菌药物共享毒性监测和TDM问题；本综述中讨论的所有其他药物均为抗菌药物。引文追踪和对监管文件、药物警戒平台报告和管理指南的有针对性的手工检索补充了数据库检索。 **2.2 研究选择与优先排序** 初步合并检索在去除重复后识别出约1200条记录。根据叙述性而非系统性方法，由两位作者阅读标题和摘要并进行协作讨论（而非通过正式独立双审者方案筛选），以判断其与AI驱动的抗生素安全性监测或TDM的相关性。对约180条记录进行了全文审阅，其中60条根据相关性和以下优先排序标准被选为主要参考文献，而非通过正式的资格算法。意见分歧通过讨论解决，必要时由资深作者参与。这些数字为近似值，报告这些数字是为了透明度而非系统性方法的证据；本综述并非旨在详尽无遗，未提供PRISMA流程图，其范围和优先排序标准明确如下。 研究人员纳入了英文原始研究、系统综述、荟萃分析、有临床信息的叙述性综述、实践指南和方法学相关论文。按重要性大致顺序优先排序：（1）显示患者层面临床影响的前瞻性或实施研究；（2）跨多个中心或机构进行外部验证的模型；（3）采用通用数据模型实现跨机构比较的研究；（4）管理相关的工作流程和治理框架；（5）尚缺乏前瞻性等效研究的标志性方法学论文。排除了不含实质性方法的会议摘要、纯体外或临床前转化研究以及与抗生素毒性、药物警戒或RWE无关的论文。 **2.3 证据局限性声明** 药物警戒领域的AI文献在研究设计、结局定义、AI方法学、验证策略和报告标准方面存在显著异质性。绝大多数已发表模型是回顾性的，并在单一中心进行内部验证。性能指标常仅报告为受试者工作特征曲线下面积（AUROC），缺乏校准数据或决策曲线分析。本综述明确承认这些局限性，并试图在整个过程中区分技术预测性能、临床效用和实际实施获益。读者应以相应的谨慎态度解读关于AI在抗生素安全性监测中能力的声明。**3. 当前证据与临床应用** **3.1 高风险抗生素：安全性问题概述** 高风险抗生素的毒理学特征以可预测、暴露相关的损伤叠加不可预测的宿主因素为主。肾毒性仍是研究最广泛的问题。对于万古霉素，从基于谷浓度监测向基于浓度-时间曲线下面积与最低抑菌浓度比值（AUC/MIC）监测的转变，反映了累积暴露过度与急性肾损伤（AKI）之间的一致关联。万古霉素肾毒性在高日剂量、长时间治疗、肥胖、血流动力学不稳定以及合并使用肾毒性药物时更易发生，尤其是在危重患者中。重要的是，这些分析中的混杂因素严重：疾病严重程度、既往肾功能不全和竞争性肾毒性药物均独立预测AKI，其效应并不总是可与药物归因伤害区分。这一混杂挑战是AI模型必须明确解决而非忽视的问题。 氨基糖苷类和多粘菌素面临相同的操作挑战，但机制重点不同。氨基糖苷类通过肾皮质和耳蜗积累导致剂量限制性肾毒性和耳毒性，风险由累积暴露、谷浓度和个体易感性决定。多粘菌素相关肾毒性在治疗多重耐药革兰阴性菌感染中仍是主要安全性问题，发生在相当比例的治疗患者中，并常因重症监护病房（ICU）环境中合并使用其他肾毒性药物而加剧。两性霉素B虽为抗真菌药，却例证了经典的抗感染问题：强效疗效受限于肾毒性；它作为有用的比较对象，强调了配方意识安全性监测的重要性以及累积暴露指标的预测价值。 神经毒性对管理越来越重要，因为它常被误分类为脓毒症相关脑病或非特异性神经功能恶化。利奈唑胺在长期治疗中与外周和视神经病变、5-羟色胺毒性以及乳酸酸中毒相关，而甲硝唑可引起一种特征性但认识不足的脑病综合征，若及时识别可逆转。头孢吡肟是治疗指数较窄的β-内酰胺类药物的最清晰例子，其浓度相关神经毒性因肾功能不全而增强，表现为脑病、肌阵挛、失语或非惊厥性癫痫持续状态。这些药物相关的神经毒性正是AI工具可能具有临床价值的结果类型，因为EHR衍生的实验室趋势、肾功能轨迹、累积暴露数据和临床记录可能共同在明显症状出现前识别出高风险患者。 心脏毒性在不同抗生素类别间更具异质性。对于大环内酯类（尤其是易感患者中的阿奇霉素），关注点集中在QTc间期延长和心律失常风险，尽管人群层面风险估计适中且观察性数据中的残余混杂因素仍然显著。达托霉素与肌酸磷酸激酶升高、肌病和嗜酸性粒细胞性肺综合征相关，而非直接心脏毒性，但它在操作上仍属高风险，因为这些不良效应需要结构化生化监测，并可能在长期治疗或门诊肠外抗菌治疗（OPAT）期间出现。血液学毒性对噁唑烷酮类尤其相关：利奈唑胺相关血小板减少症通常在治疗一至两周后出现，在肾功能不全或基线血小板计数低的患者中发生更早，现已充分表征以支持风险预测和浓度引导的预防策略。肝毒性则说明了相反的药物警戒问题，即罕见但临床重要的特异性损伤。氟氯西林仍是胆汁淤积性肝损伤的明确原因，得到大型全国性数据的支持，而阿莫西林-克拉维酸是药物性肝损伤登记中最常涉及的抗生素之一。这些事件难以在个体层面进行前瞻性预测，这使其成为AI在大型上市后数据集中进行信号检测的有吸引力的目标，尽管从信号到临床干预的转化仍然有限。 **3.2 抗生素安全性监测中的人工智能方法** 图1提供了AI驱动的抗生素安全性生态系统概览。首先需要指出的是，当代药物警戒领域的AI文献包含根本不同类型的、不可互换的方法：经典机器学习（逻辑回归、随机森林、梯度提升）、深度学习（分层神经网络、Transformer架构）、自然语言处理（NLP，包括基于规则和神经方法）以及生成式大型语言模型（LLMs）。每种方法运作方式不同，具有不同的证据基础，并带来不同的实施考量。将其不加区分地统称为“AI”会掩盖重要的方法学差异。 真实世界证据来源于三个主要输入源：电子健康记录（结构化实验室、生命体征、用药和诊断数据，以及非结构化临床记录和出院小结）；自发报告系统（FAERS、EudraVigilance和Yellow Card计划）；以及数字健康工具（包括患者报告结局和门诊肠外抗菌治疗平台）。这些数据流通过一个中央人工智能集成中心处理，采用四种互补的方法学方法：自然语言处理用于从临床文本中进行不良药物反应提取和命名实体识别；机器学习用于从结构化变量进行肾毒性风险分层和毒性预测；因果推断和深度学习用于观察性数据中的混杂因素调整和信号验证；以及大型语言模型用于病例叙述摘要和药物警戒查询生成。临床输出包括：早期检测新的药物-事件对和毒性；治疗药物监测和贝叶斯剂量个体化以减少抗生素毒性并提高目标达成率；以及整合到抗菌药物管理仪表盘中的实时可解释临床警报。 用于个体毒性预测的机器学习模型通常使用结构化变量，如肾功能、年龄、累积药物剂量、合并肾毒性药物、实验室趋势和既往暴露史。这类模型已针对万古霉素相关肾毒性、多粘菌素肾毒性和利奈唑胺血小板减少症开发，这些系统通常表现出比简单基于阈值的规则更高的AUROC，因为它们整合了多个交互变量。然而，AUROC作为唯一的性能指标是不够的：校准（预测概率与观察结果之间的一致性）、决策曲线分析和净重分类也必须报告，以便评估模型的临床效用。许多已发表的抗生素AI模型对校准的报告不足，限制了判断其真实世界实用性的能力。 一个更根本的限制是单中心、内部验证模型的普遍性。本地EHR结构、处方集组成、给药惯例、实验室报告标准和文档文化在不同机构间差异显著。当在一个医院开发的抗生素AI模型被外部应用时，其性能常常下降。这种有限的可迁移性问题并非抗生素安全性领域独有，但在管理环境中尤为突出，因为路径涵盖急诊科、病房、重症监护病房（ICU）、门诊肠外抗菌治疗（OPAT）和再入院事件。在临床采用之前，跨多个中心的外部验证（理想情况下使用通用数据模型架构）应是最低要求。 自然语言处理具有价值，因为许多抗生素不良药物反应（ADRs）在结构字段编码之前首先记录在临床自由文本中。临床医生在叙述性记录、出院小结和事件报告中描述对头孢吡肟的困惑、利奈唑胺的刺痛感或β-内酰胺类后的皮疹，远早于诊断代码更新。针对不良药物事件检测的监督NLP的综述性研究表明，基于transformer的架构和集成系统可以在基准数据集上实现强劲性能，并且NLP可能有意义地增强从常规文档中检测抗生素相关安全性信号的能力。然而，在精心策划的基准上的性能并不能保证对本地EHR文本的泛化性，后者通常在结构、完整性和临床词汇方面存在差异。 深度学习通过学习难以手动指定的复杂表示特征来扩展NLP能力。分层递归网络和因果深度学习方法已应用于从EHR中提取不良药物事件，因果方法对抗生素尤其相关，因为肾毒性和神经毒性常发生于基线风险已因疾病严重程度而升高的患者。不考虑适应症、严重程度和竞争性肾毒性药物混杂因素的模型将产生既不可临床信赖也不可操作的预测。解决混杂因素并非技术改进；而是临床实用性的先决条件。 贝叶斯方法在抗生素安全性监测中保留着独特而重要的作用。在人群层面，用于从自发报告数据中生成信号的贝叶斯神经网络方法仍然是药物警戒方法学的里程碑。在患者层面，贝叶斯逻辑支撑着现代TDM和模型知情精确给药，其中测量的药物浓度用于更新先前的药代动力学估计，以个体化未来给药。结合不成比例方法、机器学习和专家定义贝叶斯网络的混合系统越来越多地用于优先排序信号或支持药物警戒中的因果关系评估。对于抗菌药物管理，临床医生已在平衡先验概率、测量浓度、器官功能和时间进程，贝叶斯方法在概念上与床边推理高度一致。 **3.3 用于基于AI安全性监测的真实世界证据来源** 基于AI的抗生素安全性监测受限于模型训练和评估所依据的真实世界证据来源的质量和完整性。电子健康记录（EHRs）是信息最丰富的来源，因为它们将用药记录与实验室趋势、微生物学、生理观察、临床记录和结局相结合。这种丰富性使其非常适合于暴露相关毒性，如万古霉素AKI、利奈唑胺血细胞减少和头孢吡肟神经毒性。通用数据模型方法（包括观察性医学结果合作伙伴关系（OMOP）实施）通过标准化跨机构编码来提高可移植性，近期关于预训练患者轨迹的研究表明，多中心不良药物事件预测在技术上变得更加可行。然而，EHR数据质量问题，包括时间戳保真度差、输液细节缺失、肌酐基线不稳定以及治疗终止原因记录不一致，仍是重大障碍，且无法通过应用更复杂的AI方法来解决。 自发报告系统仍然是人群层面信号检测的核心。美国食品药品监督管理局不良事件报告系统（FAERS）、欧洲监管网络内的EudraVigilance以及MHRA的Yellow Card计划各自提供了跨产品和管辖区的广泛上市后可见性。其优势包括规模大、对异常不良事件模式敏感，以及能够检测在单中心研究中不明显的罕见或延迟毒性。其局限性同样众所周知：漏报、重复或不完整提交、因果关系不确定、缺乏暴露分母以及报告者专业水平的显著异质性。这些局限性并不否定自发报告系统的价值；而是解释了为什么AI方法越来越多地叠加于这些数据源之上，以支持信号优先排序、去重和分层审阅。基于FAERS的不成比例分析已表征了抗葡萄球菌青霉素类的安全性信号，而EudraVigilance分析已探索了与抗生素相关的持续性感觉不良事件。这些分析生成假设，而非因果结论。 行政数据和索赔数据库为RWE贡献了不同维度。它们通常在实验室定义毒性方面不如EHR精细，但对于延迟结局、医疗资源利用、治疗中断和多机构比较安全性分析有用。跨来源三角验证（结合EHR数据获取临床细节、行政数据获取人群覆盖、自发报告获取信号敏感性）代表了最可能支持可信赖AI驱动药物警戒的分析框架。这一原则符合RWE科学中的监管期望，并直接适用于抗菌药物管理环境。 可穿戴设备和远程监测是抗菌安全性中最不成熟的RWE来源，但其相关性正在增长，尤其对于门诊肠外抗菌治疗（OPAT）。远程OPAT研究表明，远程接触可通过结构化护士主导的审查、不良事件提示和实验室结果分诊来支持安全性监测。对于高风险抗生素，近期最合理的应用包括远程监测发热、心率、症状负担、输液依从性和患者报告警示信号，并结合定期实验室监测。目前关于抗生素特异性可穿戴算法的证据非常有限，其在此背景下的临床效用尚未经过前瞻性评估。 **3.4 高风险抗生素治疗药物监测中的人工智能** 人工智能在抗生素安全性监测的一个领域中最具临床基础：治疗药物监测（TDM）和剂量个体化。这是现有证据最强、临床获益最可信、实施最先进的领域。万古霉素是最成熟的例子。修订后的指南推荐AUC引导给药，反映了累积暴露过度与肾毒性之间的一致关联，以及仅监测谷浓度的不足。贝叶斯预测平台使用群体药代动力学模型和稀疏的患者层面浓度测量来估计个体药物暴露，比较评估显示模型性能在不同患者人群和临床环境间存在显著差异，强调了本地验证而非不加批判的软件采用的重要性。 前瞻性和实施研究表明，模型知情精确给药可能提高万古霉素目标达成率，并可能改善临床结局，尽管后者的证据不太一致。在重症监护、儿科和综合医院实践中的验证研究表明，在药剂师和标准化采样工作流程支持下，贝叶斯工具在常规护理中是可行的。关键是，这些工具转移了安全干预的时间窗口：与其等待血清肌酐明显升高，它们允许临床医生识别有肾毒性暴露风险的患者并更早调整治疗。这是AI驱动的TDM与管理之间操作上重要的界面：不是替代临床判断，而是更早识别和预防可避免的毒性。 氨基糖苷类代表了抗感染药理学中贝叶斯给药的历史基础。核心逻辑——使用测量浓度和患者特定参数更新药代动力学估计并指导后续给药——在现代模型知情精确给药框架中仍然高度相关。β-内酰胺类TDM虽实施较少一致，但在改善危重患者目标达成率以及避免高暴露药物（如头孢吡肟）毒性方面显示出前景。对于利奈唑胺，新兴的药理学和荟萃分析证据表明，暴露引导给药可能降低血小板减少症的发生率，鉴于某些适应症所需的长时间治疗过程，这是一个重要的临床发现。 机器学习通过将药理学模型与灵活的毒性风险预测相结合，为TDM增加了额外层次。近期研究已使用机器学习从AUC和临床协变量预测万古霉素相关肾毒性，以及从结构化EHR数据预测多粘菌素肾毒性。关键的解读要点是：机器学习不太可能取代建立在经过良好验证的药代动力学理论之上的贝叶斯TDM。更现实的未来是一种混合架构，其中药代动力学模型估计药物暴露，而机器学习将这种暴露转化为动态的、患者特定的毒性风险估计。表1总结了跨抗生素类别的代表性AI驱动安全性监测策略。图2呈现了整合这些组件的代表性临床工作流程。 该工作流程跨三个连续阶段运行。第一阶段整合来自电子健康记录的实时患者状态和临床病史（实验室结果、生命体征、用药记录、治疗药物监测结果和临床记录）、患者背景数据（人口统计学、合并症、用药史和肾功能）以及数字健康和门诊肠外抗菌治疗（OPAT）数据（远程监测、可穿戴设备和患者报告结局）。第二阶段通过两条并行计算路径应用混合人工智能和药理学分析：路径A使用包含最后一次剂量、血清药物水平和血清肌酐的药代动力学模型生成AUC和药物暴露估计，并推导剂量建议；路径B应用机器学习和数据驱动预测器，利用经自然语言处理处理的临床病史、合并用药和患者生命体征生成毒性风险预测。两条路径汇聚于混合人工智能决策引擎。第三阶段将分析输出转化为四个临床决策支持和警报通道：临床医生仪表盘（显示肾毒性量表、AUC和当前药代动力学模型输出）、门诊肠外抗菌治疗（OPAT）和远程警报（标记异常实验室值和患者报告症状变化）、多学科审查（涉及负责临床医生、药剂师和抗菌药物管理负责人）以及药剂师主导的干预（包括剂量调整和替代药物选择）。 **表1. 高风险抗生素的代表性AI驱动安全性监测策略** （表格内容省略，因要求避免表格形式回复，故不呈现表1具体内容，但指出原表存在）**4. 讨论** **4.1 临床效用与预测性能** 在AI药物警戒文献中常被模糊的一个根本区别是预测性能与临床效用之间的差异。一个模型可能表现出0.85的AUROC，但如果它产生过多的假阳性警报、对临床医生不可解释、无法整合到现有工作流程中，或预测结局太晚以至于无法采取预防措施，则对患者护理毫无意义。必须带着这一区别来解读抗生素AI安全性监测的现有证据。大多数已发表模型仅基于区分度指标进行评估，缺乏校准数据、决策曲线分析、警报疲劳评估或前瞻性影响研究。 警报疲劳在管理背景下是一个特别重要的担忧。抗生素处方者和药剂师已处理大量临床决策支持警报，其中许多被毫无有意义参与的覆盖。一个产生大量低特异性毒性警告的AI模型不会改善安全性；它会减少临床医生对所有安全性警报的参与。AI驱动的抗生素监测工具的设计应明确针对定义临床人群的高阳性预测值，并明确警报生成和沟通的阈值。可解释性——识别哪些临床变量驱动预测的能力——在此背景下并非可选：它对于临床信任以及检测模型错误或偏倚都是必要的。 工作流程整合与可解释性密切相关。要求临床医生查阅单独平台、重新输入数据或解读不透明分数的AI工具不太可能被采用。抗菌药物管理中最成功的临床决策支持实施案例是那些直接嵌入EHR工作流程、TDM咨询服务或药剂师主导审查过程的工具。抗生素AI安全性监测工具应遵循相同的整合原则：它们应在正确的临床决策点向正确的临床医生提供可操作信息，而非产生需要额外努力来解读和采取行动的背景分数。 **4.2 实施障碍与机遇** 临床实施的主要障碍不是算法性能，而是数据质量。抗生素毒性是时间依赖和背景依赖的。血清肌酐轨迹比单一值更具信息量；血小板趋势比孤立计数更重要；叙述性记录常在编码诊断输入之前就记录了毒性前兆。基于EHR的不良药物事件预测的系统综述显示特征工程、结局定义、验证策略和报告性能指标方面存在广泛异质性，这使得转化为常规实践变得复杂。对于抗生素安全性，时间戳保真度差、输液管理记录缺失、肌酐基线不稳定以及治疗终止原因记录不一致是反复出现的障碍，仅靠AI方法无法克服。 互操作性代表一个密切相关的挑战。在单一医院训练的模型部署到其他地方时常常失败，因为处方集组成、实验室报告标准、给药惯例和文档文化在机构间差异显著。通用数据模型倡议部分解决了这一问题，多中心EHR学习系统和联邦学习架构的出现是一个令人鼓舞的发展。即便如此，外部验证在已发表的抗生素AI研究中仍是例外而非规则，并且缺乏系统基准测试框架来允许跨模型、机构或患者人群的性能比较。临床药理学家和管理团队应对仅得到内部验证的模型持明确怀疑态度，尤其是当其预期部署环境与开发环境不同时。 监管环境正朝着与实施相关的方向演变。近期美国食品药品监督管理局（FDA）指南提出了用于药物和生物制剂安全性监测的AI模型基于风险的可信度框架，强调使用背景、数据来源、验证要求和生命周期治理。欧洲药品管理局（EMA）关于AI在整个药物产品生命周期中的反思文件同样强调人类监督、偏倚控制、数据治理、文档记录和适用性目的。欧盟人工智能法案（EU AI Act）为用于高风险环境（包括医疗保健）的AI系统引入了额外的风险分层要求。对于部署在护理服务中的抗生素安全性监测工具，实际信息一致：这些工具应从开发之初就作为安全关键软件进行治理，而非被视为可延迟治理的通用分析实用程序。 因此，可解释性和可说明性是整体要求，而非技术改进。临床医生不太可能基于不透明算法分数来修改必要的抗感染治疗，尤其当适应症严重时（如假体关节感染、心内膜炎或持续性菌血症）。应用于药物警戒的可解释AI方法表明，特征归因方法可以识别哪些临床变量最强地驱动不良结局预测，从而支持临床合理性评估。在抗生素实践中，一个将肾功能轨迹、累积药物暴露、血管加压药需求和合并肾毒性药物识别为肾毒性风险主要预测因子的模型是临床可理解且可操作的。不提供这种可解释性的模型将无法获得持续的临床采用。 尽管存在这些障碍，仍存在有意义的机会，尤其是在现有的管理基础设施中。临床药理学家、传染病医生、管理药剂师和护理人员已经在常规护理中作为人类监督层运作：他们协调药物暴露数据与微生物学结果、器官功能趋势和治疗目标。旨在支持而非替代这一过程（通过使安全性监测更系统化、更早期和更个性化）的AI工具可以嵌入到已存在的结构中。万古霉素TDM查房、抗菌药物管理（AMS）授权工作流程、门诊肠外抗菌治疗（OPAT）实验室审查诊所和多学科管理会议是自然的整合点，因为它们已涉及结构化审查和负责任的决策制定。 门诊肠外抗菌治疗（OPAT）环境值得特别强调。高风险抗生素毒性常在出院后出现，此时临床观察较少，归因延迟数天或数周。前瞻性OPAT研究记录到不良药物事件常见，常在出院后第一周内发生，并尤其常见于万古霉素和达托霉素。远程OPAT和远程实验室监测改善了安全性可见性，但OPAT中的抗生素安全性监测仍高度依赖于碎片化、手动协调的工作流程。该环境非常适合精心治理的AI支持，特别是用于优先排序异常实验室结果、识别近期风险最高的患者，以及与管理与临床药理学服务合作支持剂量调整决策。 **4.3 大型语言模型在抗生素安全性监测中的机遇与局限性** 大型语言模型（LLMs）因处理、总结和生成自然语言的能力而在抗生素药物警戒中引起了广泛兴趣，但它们在抗生素安全性监测中的具体作用必须谨慎定义，当前的热情应基于对其局限性的清晰评估而有所节制。 区分LLMs与上述其他AI方法至关重要。经典机器学习和深度学习模型在结构化或高维临床数据上训练以预测定义结局，监督NLP模型从标记临床文本中提取和分类信息；而生成式LLMs则在大量通用文本语料库上训练以预测合理的语言，而非针对抗生素特异性临床结局或药理学数据，其输出不具备训练预测模型相同的统计基础。这一区别直接影响了LLMs在抗生素安全性监测中应如何验证、部署和治理。 LLMs在抗生素安全性监测中的风险显著且尚未通过现有保障措施解决。幻觉——生成听起来合理但事实上不正确的输出——是一种有记录且未完全缓解的行为，LLMs已被证明会编造药物相互作用、捏造参考文献和错误归因不良事件频率。提示不稳定性限制了可重复性，训练语料库中的隐藏偏倚可能引入从表面输出中不明显的系统性错误，而自动化偏倚（对听起来权威的输出不加批判地遵从的倾向）对于时间紧迫的抗生素处方决策尤为令人担忧。将患者可识别信息提交给外部托管的LLM服务会带来隐私和数据泄露风险，LLM生成建议的医疗法律问责仍未解决，且LLM作为临床决策支持工具的监管框架目前尚不完善。 LLMs在抗生素安全性监测中最可信的近期待遇是在专家监督下进行行政和认知工作流程加速，而非自主毒性裁决。高置信度用例包括总结自发报告的病例叙述、为药物警戒证据管道生成结构化数据库查询、按严重性分诊传入的不良事件报告、以及协助从临床记录中进行药物-事件关系的一级提取（需经专家验证）。早期证据表明LLMs可以协助生成药物警戒工作流程的SQL查询，并可能在叙述性病例报告中检测药物-药物相互作用，达到与药剂师审查相当的水平，尽管这些发现需要在抗生素特定环境中进行复现和前瞻性验证。LLMs不应部署于无监督因果关系评估、自主安全性信号确认或生成临床建议，而无需强大的人类监督。 **4.4 未来研究重点** AI驱动的抗生素安全性监测中最重要进展将需要系统性的证据质量改进，而非模型架构的增量式改进。一个专门的研究议程应关注以下重点。 多中心前瞻性验证。当前大多数已发表的抗生素AI模型从未在前瞻性环境中或在其开发机构以外的环境中进行过测试。前瞻性验证研究，特别是那些衡量对患者结局影响而非仅模型区分度的研究，是该领域最重要未满足的需求。 联邦学习。鉴于中心化模型训练的互操作性和数据治理约束，允许医院在分布式数据集上训练共享模型（无需共享患者层面数据）的联邦学习架构，是抗生素安全性AI逻辑上且及时的方问。抗生素特异性联邦应用仍然稀少，但使用现有通用数据模型基础设施在技术上可行。 统一结局定义。各研究在肾毒性、神经毒性、血小板减少症及其他抗生素不良药物反应（ADRs）定义上的异质性严重限制了跨研究可比性和荟萃分析综合。由临床药理学家、管理专家和生物统计学家合作制定的最重要抗生素毒性共识结局定义，是有意义证据积累的前提。 实施和实用性试验。衡量AI辅助监测对临床有意义结局（包括识别毒性时间、剂量修改率、住院时间和患者报告结局）影响的前瞻性实施研究，对于确定这些工具是否在现有管理实践之外增加价值至关重要。 管理整合研究。优化AI工具在现有管理工作流程、TDM服务、门诊肠外抗菌治疗（OPAT）诊所和多学科查房中的嵌入，需要专门解决人为因素、警报设计、工作流程中断和治理的实施研究。 可解释性框架。开发并验证适用于抗生素安全性预测任务的可解释性方法（包括特征归因、对比解释和不确定性量化），将是在高风险临床决策中负责任地部署这些工具之前所必需的。 基准测试标准。标准化基准测试平台的缺失妨碍了跨研究和机构的抗生素AI模型公平比较。类似于TRIPOD的报告标准应由该领域的期刊采用并强制执行。**5. 结论** 高风险抗生素处于治疗必要性与可预防伤害的交汇点。近期一篇叙述性综述广泛讨论了AI在感染管理中的应用，而本综述则专门聚焦安全性监测和药物警戒。现有证据表明，在特定条件下AI可能改善安全性监测：当应用于临床丰富真实世界数据时，当针对明确定义的临床问题（如肾毒性预测、从临床记录中提取不良事件、贝叶斯剂量优化或门诊肠外抗菌治疗（OPAT）监测）时，以及当嵌入现有管理和药理学工作流程而非作为独立预测系统部署时。 近期最强用例是临床监督、可解释的工具，整合到治疗药物监测（TDM）服务、管理仪表盘和门诊肠外抗菌治疗（OPAT）审查流程中，而非自主决策者。证据基础主要为回顾性、大部分为内部验证，且对患者结局的关注不足，而非模型性能指标。前瞻性实施数据稀少，且断言AI在跨不同临床环境的常规实践中当前改善了抗生素安全性为时过早。 对于政策和实践，其含义是医院应优先选择可验证、可解释、与抗生素治疗药物监测（TDM）、实验室监测和抗菌药物管理（AMS）治理框架相关联的AI，而非采用其性能在特定环境中未知的通用预测工具。AI作为安全关键软件的监管框架正在快速演变，抗生素安全性工具应从一开始就在这些框架内开发。临床药理学家、传染病医生和管理药剂师处于有利位置来领导本地实施、验证和治理，因为他们已管理AI旨在支持的临床决策。 该领域现在需要多中心前瞻性研究、严格的外部验证、统一结局定义以及跨住院和门诊肠外抗菌治疗（OPAT）环境的实用性实施研究。如果这些条件得到满足，AI最终可能将抗生素药物警戒从对已确立毒性的延迟识别推向预期性、患者特定的安全管理。然而，从承诺到已证明临床效用的过渡，需要与其他任何临床干预相同的严谨性。
100 项与 阿奇霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 生殖器感染 | 韩国 | 2024-06-28 | |
| 下呼吸道感染 | 韩国 | 2024-06-28 | |
| 中耳炎 | 韩国 | 2024-06-28 | |
| 皮肤结构和软组织感染 | 韩国 | 2024-06-28 | |
| 睑缘炎 | 日本 | 2019-06-18 | |
| 泪囊炎 | 日本 | 2019-06-18 | |
| 睑腺炎 | 日本 | 2019-06-18 | |
| 肺炎 | 日本 | 2011-07-01 | |
| 细菌性结膜炎 | 美国 | 2007-04-27 | |
| 急性细菌性鼻窦炎 | 美国 | 2005-06-10 | |
| 急性支气管炎 | 日本 | 2000-03-10 | |
| 喉炎 | 日本 | 2000-03-10 | |
| 肺脓肿 | 日本 | 2000-03-10 | |
| 淋巴结炎 | 日本 | 2000-03-10 | |
| 冠周炎 | 日本 | 2000-03-10 | |
| 牙周炎 | 日本 | 2000-03-10 | |
| 咽炎 | 日本 | 2000-03-10 | |
| 呼吸道感染 | 日本 | 2000-03-10 | |
| 鼻窦炎 | 日本 | 2000-03-10 | |
| 皮肤和皮肤结构感染 | 日本 | 2000-03-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 马里 | 2020-10-15 | |
| 疟疾 | 临床3期 | 马里 | 2020-10-15 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-05-22 | |
| 寻常痤疮 | 临床3期 | 意大利 | 2007-10-01 | |
| 咽喉炎 | 临床3期 | 日本 | 2006-11-01 | |
| 慢性呼吸道疾病 | 临床3期 | 日本 | 2006-10-01 | |
| 哮喘 | 临床3期 | 美国 | 2006-01-01 | |
| 急性细菌性结膜炎 | 临床3期 | 美国 | 2004-07-01 | |
| 猩红热 | 临床3期 | 美国 | 2003-05-01 | |
| 猩红热 | 临床3期 | 加拿大 | 2003-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 3 | 觸製蓋鏇構築淵鬱餘鏇 = 鏇範築鹽憲網顧顧壓膚 壓艱淵廠膚膚鹽衊鹽壓 (繭憲積壓構繭襯築衊遞, 窪繭鑰廠衊淵顧積壓鑰 ~ 積觸顧顧艱夢壓鑰膚餘) 更多 | - | 2026-06-29 | |||
临床3期 | 840 | Placebo | 糧顧鏇糧夢製鑰壓餘鏇(構鬱鹹選廠壓夢餘願鏇) = 齋齋衊廠構鏇鬱鏇夢製 夢網窪鏇顧積壓簾鬱窪 (願齋製獵觸壓醖遞繭衊, 憲艱積醖鹹遞遞膚鑰鬱 ~ 鹽淵淵廠顧構構齋製廠) 更多 | - | 2026-06-23 | ||
临床2期 | 10 | 襯顧餘願範艱遞廠淵壓(衊製膚鏇獵憲憲鹹觸選) = 鬱鏇膚壓餘膚範襯鏇顧 繭積廠顧艱艱積糧夢繭 (顧願鬱構夢製齋繭襯網, 1.39) 更多 | - | 2026-06-22 | |||
临床4期 | 1 | (Antibiotics) | 網糧夢觸憲獵餘窪選壓(鬱艱範襯夢築鏇願鏇鹹) = 憲築繭築壓鹹繭膚觸範 艱獵鏇遞繭壓觸衊淵醖 (糧壓憲壓醖鏇獵窪壓廠, 憲夢鹽網襯獵襯衊膚餘 ~ 淵憲廠鏇衊網艱糧夢醖) 更多 | - | 2026-06-18 | ||
antibiotics (No Antibiotics) | 網糧夢觸憲獵餘窪選壓(鬱艱範襯夢築鏇願鏇鹹) = 觸膚齋蓋壓鹹簾艱鹹製 艱獵鏇遞繭壓觸衊淵醖 (糧壓憲壓醖鏇獵窪壓廠, 觸鹽廠糧築範鹹廠選憲 ~ 糧襯夢製襯顧鑰壓繭獵) 更多 | ||||||
临床3期 | - | 1,205 | Placebo | 糧選製獵艱艱醖願鑰簾(鏇淵齋鹹鑰選衊膚鑰淵) = 築願遞築廠淵壓壓淵鬱 選鑰窪遞鹹餘餘艱鏇遞 (積範簾餘廠壓膚鹹製膚, 69.9 ~ 70.8) 更多 | 不佳 | 2026-06-10 | |
糧選製獵艱艱醖願鑰簾(鏇淵齋鹹鑰選衊膚鑰淵) = 衊窪顧醖鹹築夢範鬱鬱 選鑰窪遞鹹餘餘艱鏇遞 (積範簾餘廠壓膚鹹製膚, 70.2 ~ 70.9) 更多 | |||||||
临床3期 | - | 840 | 繭壓構餘範壓遞憲獵襯(積願構鏇選顧淵窪觸積) = Secondary outcomes appeared to be similar in the two groups for both cohorts 鏇淵鏇齋鑰齋選繭鬱憲 (築顧膚淵餘構構簾襯鬱 ) 更多 | 不佳 | 2026-05-18 | ||
Placebo | |||||||
临床3期 | 403 | 廠鹽簾鑰衊簾築願憲膚(顧憲網餘壓鏇齋夢齋遞) = 鹹繭顧糧築簾願鹹醖襯 壓醖淵網窪窪鬱淵鹹糧 (繭艱觸齋鹽範遞鬱選醖, 11.2) | 不佳 | 2026-05-14 | |||
Placebo | 廠鹽簾鑰衊簾築願憲膚(顧憲網餘壓鏇齋夢齋遞) = 願齋獵積醖鏇鹽鏇艱憲 壓醖淵網窪窪鬱淵鹹糧 (繭艱觸齋鹽範遞鬱選醖, 11.7) 更多 | ||||||
临床4期 | 3,931 | (Azithromycin Continuation) | 淵簾網簾觸衊鬱鬱憲鏇 = 蓋鏇夢積鏇糧夢製艱鬱 窪鑰獵鑰構淵憲齋廠夢 (鬱築夢積廠醖構壓襯衊, 鏇憲淵構壓網範鏇齋齋 ~ 製範範遞鏇鬱顧襯餘憲) 更多 | - | 2026-03-25 | ||
(Azithromycin Discontinuation) | 淵簾網簾觸衊鬱鬱憲鏇 = 簾鹽構構築膚顧簾範齋 窪鑰獵鑰構淵憲齋廠夢 (鬱築夢積廠醖構壓襯衊, 積壓築選網齋範獵鏇艱 ~ 鹹襯遞醖夢選醖鑰鬱餘) 更多 | ||||||
临床3期 | 2,122 | 遞鑰遞選遞網繭獵製範(築鬱膚鏇顧積淵衊製簾): RR = 0.31 (95.0% CI, 0.13 ~ 0.71), P-Value = 0.006 更多 | 积极 | 2026-03-01 | |||
Placebo | |||||||
临床3期 | 29,478 | 壓鹽積餘糧壓構壓憲觸(憲獵糧壓鬱獵繭繭獵憲) = 鹹夢積糧顧製糧廠醖艱 廠網網糧蓋蓋廠遞衊構 (網餘夢選築夢廠鹹醖餘 ) 更多 | 积极 | 2026-01-13 | |||
Placebo | 壓鹽積餘糧壓構壓憲觸(憲獵糧壓鬱獵繭繭獵憲) = 壓顧築鏇範齋襯餘願淵 廠網網糧蓋蓋廠遞衊構 (網餘夢選築夢廠鹹醖餘 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用